

A depression rating scale for schizophrenics

Schizophrenia Research

3, 247-251

DOI: 10.1016/0920-9964(90)90005-r

Citation Report

#	ARTICLE	IF	CITATIONS
1	Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 1992, 6, 201-208.	2.0	570
2	Assessing Depression in Schizophrenia: The Calgary Depression Scale. British Journal of Psychiatry, 1993, 163, 39-44.	2.8	901
3	Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research, 1994, 11, 239-244.	2.0	229
4	Depression in schizophrenia: a comparison of three measures. Schizophrenia Research, 1996, 20, 205-209.	2.0	97
5	A psychometric comparison of the Calgary depression scale for schizophrenia and the Hamilton depression rating scale. Schizophrenia Research, 1996, 19, 205-212.	2.0	193
6	Depressive symptoms in acute schizophrenic inpatients. Schizophrenia Research, 1997, 25, 131-139.	2.0	32
7	Insight, neurocognitive function and symptom clusters in chronic schizophrenia. Schizophrenia Research, 1997, 27, 37-44.	2.0	116
8	Recent advances in the understanding of negative symptoms in schizophrenia. Journal of the American Psychiatric Nurses Association, 1997, 3, 111-117.	1.0	0
9	Recent Advances in the Understanding of Negative Symptoms in Schizophrenia. Journal of the American Psychiatric Nurses Association, 1997, 3, 111-117.	1.0	0
10	Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia Scale (BRMES). Journal of Psychiatric Research, 1998, 32, 369-378.	3.1	29
11	Speaking behavior and speech sound characteristics in acute schizophrenia. Journal of Psychiatric Research, 1998, 32, 89-97.	3.1	29
12	Calgary Depression Scale for Schizophrenia: a study of the validity of a French language version in a population of schizophrenic patients. Acta Psychiatrica Scandinavica, 1998, 97, 36-41.	4.5	51
13	A scale to measure the impact of a schizophrenic illness on an individual's self-concept. Archives of Psychiatric Nursing, 1998, 12, 41-49.	1.4	57
14	Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia. Schizophrenia Research, 1998, 32, 31-39.	2.0	85
15	Depression in people with first-episode schizophrenia. British Journal of Psychiatry, 1998, 172, 90-92.	2.8	282
16	The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). Journal of Psychiatric Research, 1999, 33, 433-443.	3.1	69
17	Validity and reliability of the French language version of the Positive and Negative Syndrome Scale (PANSS). Acta Psychiatrica Scandinavica, 1999, 100, 237-243.	4.5	53
18	Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale. Psychiatry Research, 1999, 89, 123-132.	3.3	33

#	ARTICLE	IF	CITATIONS
19	Three dimensions of depression in patients with acute psychotic disorders: A replication study. Comprehensive Psychiatry, 1999, 40, 449-457.	3.1	12
20	Prevalence and background factors of depression in first admitted schizophrenic patients. Acta Psychiatrica Scandinavica, 2000, 101, 153-160.	4.5	68
21	Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). Journal of Affective Disorders, 2000, 58, 107-115.	4.1	50
22	Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Annals of Clinical Psychiatry, 2000, 12, 11-18.	0.6	19
23	The Greek version of the Calgary Depression Scale for Schizophrenia. Psychiatry Research, 2000, 94, 163-171.	3.3	21
24	Depression in Patients with Schizophrenia. CNS Drugs, 2000, 14, 289-299.	5.9	16
25	Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 2000, 42, 231-239.	2.0	169
26	Comparison of four scales measuring depression in schizophrenic inpatients. European Psychiatry, 2000, 15, 274-277.	0.2	44
27	Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. Schizophrenia Research, 2001, 47, 135-140.	2.0	61
28	Depression in schizophrenia: recognition and management in the USA. Schizophrenia Research, 2001, 47, 185-197.	2.0	124
31	Use of Olanzapine for Elderly Patients With Psychotic Disorders: A Review. Annals of Clinical Psychiatry, 2001, 13, 201-213.	0.6	9
32	Electroconvulsive Therapy in Cases of Treatment-Resistant Psychosis. Canadian Journal of Psychiatry, 2001, 46, 762-763.	1.9	0
33	Depressive Factors and Their Relationships With Other Symptom Domains in Schizophrenia, Schizoaffective Disorder, and Psychotic Depression. Schizophrenia Bulletin, 2001, 27, 19-28.	4.3	36
34	Reliability and validity of the Danish version of the Calgary Depression Scale for Schizophrenia. Nordic Journal of Psychiatry, 2001, 55, 119-122.	1.3	8
35	Fluvoxamine Augmentation of Olanzapine in Chronic Schizophrenia: Pharmacokinetic Interactions and Clinical Effects. Journal of Clinical Psychopharmacology, 2002, 22, 502-506.	1.4	61
36	Neuropsychiatric syndromes in lupus. Neurology, 2002, 58, 1214-1220.	1.1	572
37	Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. Schizophrenia Research, 2002, 56, 121-127.	2.0	63
38	One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophrenia Research, 2002, 54, 231-242.	2.0	207

#	ARTICLE	IF	CITATIONS
39	Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. Schizophrenia Research, 2002, 57, 307-309.	2.0	15
40	Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication. European Psychiatry, 2002, 17, 459-465.	0.2	11
41	Characterization of depressive syndrome in schizophrenic outpatients. Revista Brasileira De Psiquiatria, 2002, 24, 18-25.	1.7	3
42	Depression, emotional blunting, and akinesia in schizophrenia. European Journal of Health Economics, 2002, 3, s99-s103.	2.8	9
43	Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatrica Scandinavica, 2002, 106, 83-96.	4.5	60
44	Negative symptoms in first episode non-affective psychosis. Acta Psychiatrica Scandinavica, 2002, 105, 431-439.	4.5	102
45	A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatrica Scandinavica, 2003, 107, 351-360.	4.5	22
46	Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatrica Scandinavica, 2003, 108, 297-303.	4.5	102
47	Cognitive behavioural group treatment for social anxiety in schizophrenia. Schizophrenia Research, 2003, 63, 121-129.	2.0	101
48	Depressive symptoms in chronic schizophrenia patients: any differences between patients with and without a major depressive episode?. European Psychiatry, 2003, 18, 137-139.	0.2	4
49	Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. Psychiatry Research, 2003, 117, 47-56.	3.3	56
50	Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus, 2003, 12, 697-703.	1.6	51
51	The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. Schizophrenia Bulletin, 2003, 29, 15-31.	4.3	549
52	Working Memory Deficit as a Core Neuropsychological Dysfunction in Schizophrenia. American Journal of Psychiatry, 2003, 160, 1809-1816.	7.2	349
53	Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Schizophrenia Bulletin, 2003, 29, 33-43.	4.3	102
54	Possible Relationship Between Testosterone and Comorbid Major Depressive Episode in Male Patients With Schizophrenia Treated With Typical Antipsychotic Medications. Clinical Neuropharmacology, 2003, 26, 291-293.	0.7	10
55	Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. International Clinical Psychopharmacology, 2003, 18, 305-313.	1.7	36
56	Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. International Clinical Psychopharmacology, 2003, 18, 305-313.	1.7	11

#	ARTICLE	IF	CITATIONS
57	Subjective Experience of Language Impairment and Psychopathology in Schizophrenia. Psychopathology, 2003, 36, 17-22.	1.5	11
58	The Hamilton Depression Rating Scale: Has the Gold Standard Become a Lead Weight?. American Journal of Psychiatry, 2004, 161, 2163-2177.	7.2	915
60	Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry, 2004, 161, 975-984.	7.2	330
61	Cognitive Functioning in Young People with First Episode Psychosis: Relationship to Diagnosis and Clinical Characteristics. Australian and New Zealand Journal of Psychiatry, 2004, 38, 501-510.	2.3	85
62	Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatrica Scandinavica, 2004, 110, 108-118.	4.5	55
63	Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatrica Scandinavica, 2004, 110, 292-298.	4.5	111
64	Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. Schizophrenia Research, 2004, 68, 349-356.	2.0	81
65	Is the intensity of Schneiderian symptoms related to handedness and speech disorder in subjects with psychosis?. Schizophrenia Research, 2004, 67, 167-173.	2.0	36
66	Neuropsychological correlates of symptom profiles in first episode schizophrenia. Schizophrenia Research, 2004, 71, 323-330.	2.0	49
67	Depressive syndrome in major psychoses: a study on 1351 subjects. Psychiatry Research, 2004, 127, 85-99.	3.3	60
68	Factor structure of the Zung Self-rating Depression Scale in first-year university students in Japan. Psychiatry Research, 2004, 128, 281-287.	3.3	53
69	Tools for measuring clinical effectiveness. European Neuropsychopharmacology, 2004, 14, S435-S444.	0.7	13
70	Adjunctive use of reboxetine in schizophrenia. European Psychiatry, 2004, 19, 366-369.	0.2	27
71	Agreement Between Self-Rated and Clinically Assessed Symptoms in Subjects With Psychosis. Journal of Nervous and Mental Disease, 2004, 192, 352-356.	1.0	61
72	Can Patients at Risk for Persistent Negative Symptoms Be Identified During Their First Episode of Psychosis?. Journal of Nervous and Mental Disease, 2004, 192, 455-463.	1.0	97
73	Negative Symptoms, Trauma, and Autobiographical Memory. Journal of Nervous and Mental Disease, 2004, 192, 745-753.	1.0	49
74	Measuring outcome priorities and preferences in people with schizophrenia. British Journal of Psychiatry, 2005, 187, 529-536.	2.8	74
75	Antipsychotic Polypharmacy: Is There Evidence for its Use?. Journal of Psychiatric Practice, 2005, 11, 248-257.	0.7	29

#	ARTICLE	IF	CITATIONS
76	Differential Hemodynamic Brain Activity in Schizophrenia Patients With Blunted Affect During Quetiapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 367-371.	1.4	30
77	Quetiapine-Associated Depression in a Patient With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2005, 28, 133-135.	0.7	7
78	Obsessive-compulsive symptoms in schizophrenia: Prevalance and clinical correlates. <i>Psychiatry and Clinical Neurosciences</i> , 2005, 59, 291-295.	1.8	117
79	The Calgary Depression Rating Scale for schizophrenia in a healthy control group: Psychometric properties and reference values. <i>Journal of Affective Disorders</i> , 2005, 88, 69-74.	4.1	30
80	Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: An fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 1-15.	1.8	68
81	Cognitive-behavioural group treatment of depression in patients with psychotic disorders. <i>Clinical Psychology and Psychotherapy</i> , 2005, 12, 465-474.	2.7	4
82	Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2005, 181, 358-363.	3.1	67
83	A community intervention for early identification of First Episode Psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2005, 40, 337-344.	3.1	62
84	The European Schizophrenia Cohort. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2005, 40, 707-717.	3.1	58
85	The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial. <i>Quality of Life Research</i> , 2005, 14, 1275-1289.	3.1	27
86	Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. <i>Neurology</i> , 2005, 64, 297-303.	1.1	163
87	Cognitive Strategies Versus Self-Management Skills as Adjunct to Vocational Rehabilitation. <i>Schizophrenia Bulletin</i> , 2005, 31, 55-66.	4.3	113
88	Clinical Profiles, Scope and General Findings of the Western Sydney First Episode Psychosis Project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 36-43.	2.3	30
89	Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2005, 56, 273-282.	2.0	106
90	Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2005, 32, 715-723.	4.3	339
91	Effects of Psychotic State and Task Demand on Prefrontal Function in Schizophrenia: An fMRI Study of Overt Verbal Fluency. <i>American Journal of Psychiatry</i> , 2005, 162, 485-494.	7.2	97
92	Is Adolescent-Onset First-Episode Psychosis Different From Adult Onset?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 782-789.	0.5	137
93	Depressive and negative symptoms in schizophrenia: different effects on clinical features. <i>Comprehensive Psychiatry</i> , 2005, 46, 304-310.	3.1	65

#	ARTICLE	IF	CITATIONS
94	Insight into illness in schizophrenia. <i>Comprehensive Psychiatry</i> , 2005, 46, 284-290.	3.1	35
95	Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia. <i>Biological Psychiatry</i> , 2005, 57, 1594-1596.	1.3	125
96	M50 sensory gating predicts negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2005, 73, 311-318.	2.0	73
97	The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. <i>Schizophrenia Research</i> , 2005, 78, 147-156.	2.0	89
100	Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes. <i>Schizophrenia Research</i> , 2006, 81, 29-39.	2.0	39
101	Suicidality in schizophrenia as a separate symptom domain that may be independent of depression or psychosis. <i>Schizophrenia Research</i> , 2006, 81, 113-114.	2.0	7
102	Impaired error monitoring contributes to face recognition deficit in schizophrenia patients. <i>Schizophrenia Research</i> , 2006, 85, 151-161.	2.0	23
103	Diagnostic validity of assessment scales for depression in patients with schizophrenia. <i>Psychiatry Research</i> , 2006, 144, 57-63.	3.3	85
104	Major depressive disorder as a co-morbid diagnosis in schizophrenia versus the diagnosis of schizoaffective disorder – depressed type. <i>African Journal of Psychiatry</i> , 2006, 8, 134.	0.1	1
105	Lamotrigine for schizophrenia. <i>The Cochrane Library</i> , 2006, , CD005962.	2.8	41
106	Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 387-392.	1.9	31
107	Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia. <i>Journal of the International Neuropsychological Society</i> , 2006, 12, 34-44.	1.8	26
108	Association Between Attitude Toward Medication and Neurocognitive Function in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2006, 29, 197-205.	0.7	29
109	A Randomized, 1-Year Follow-up Study of Olanzapine and Risperidone in the Treatment of Negative Symptoms in Outpatients with Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 238-249.	1.4	50
110	Substance Use in Persons With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2006, 194, 164-172.	1.0	137
111	Fluvoxamine as an Adjunctive Agent in Schizophrenia. <i>CNS Neuroscience & Therapeutics</i> , 2001, 7, 283-304.	4.0	41
112	Depression, suicidal behavior and insight in adolescents with schizophrenia. <i>European Child and Adolescent Psychiatry</i> , 2006, 15, 352-359.	4.7	57
114	Barriers to Employment for People With Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 411-417.	7.2	390

#	ARTICLE	IF	CITATIONS
115	A National Study of Violent Behavior in Persons With Schizophrenia. Archives of General Psychiatry, 2006, 63, 490.	12.3	648
116	Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia. Archives of General Psychiatry, 2006, 63, 1079.	12.3	1,031
117	Estrogen, Cognitive Function and Negative Symptoms in Female Schizophrenia. Neuropsychobiology, 2006, 53, 169-175.	1.9	61
118	Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. International Journal of Psychiatry in Clinical Practice, 2006, 10, 97-104.	2.4	24
119	Aripiprazole in the treatment of the psychosis prodrome. British Journal of Psychiatry, 2007, 191, s96-s101.	2.8	91
120	Suboptimal processing strategy and working-memory impairments predict abstraction deficit in schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 823-830.	1.3	9
121	Validation of the factorial structure of the Positive and Negative Syndrome Scale in use by untrained psychiatrists in routine care. International Journal of Psychiatry in Clinical Practice, 2007, 11, 53-60.	2.4	7
122	Quetiapine demonstrates good tolerability and is associated with improvements in extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics: results of a naturalistic study. International Journal of Psychiatry in Clinical Practice, 2007, 11, 112-122.	2.4	1
123	Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. American Journal of Psychiatry, 2007, 164, 1050-1060.	7.2	329
124	Selective Abnormal Modulation of Hippocampal Activity During Memory Formation in First-Episode Psychosis. Archives of General Psychiatry, 2007, 64, 999.	12.3	65
125	Cognition in Young Schizophrenia Outpatients: Comparison of First-Episode With Multiepisode Patients. Schizophrenia Bulletin, 2007, 34, 544-554.	4.3	48
126	Persistent Negative Symptoms in Schizophrenia: An Overview. Schizophrenia Bulletin, 2007, 33, 1013-1022.	4.3	366
127	What Influences Purpose in Life in First-Episode Psychosis?. British Journal of Occupational Therapy, 2007, 70, 401-406.	0.9	15
128	Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol. Cognitive Neuropsychiatry, 2007, 12, 322-338.	1.3	6
129	Emotion recognition and genetic vulnerability to schizophrenia. British Journal of Psychiatry, 2007, 191, 126-130.	2.8	138
130	Neural correlates of the misattribution of speech in schizophrenia. British Journal of Psychiatry, 2007, 190, 162-169.	2.8	119
131	Améliorer les symptômes et le tabagisme chez les personnes souffrant de schizophrénie: un manque d'effet synergique du médicament antipsychotique. Sante Mentale Au Quebec, 0, 32, 165-176.	0.1	1
132	Co-occurring SAD symptomatology and schizophrenia at high latitude: a pilot study. International Journal of Circumpolar Health, 2007, 66, 248-256.	1.2	4

#	ARTICLE	IF	CITATIONS
133	Effects of Donepezil Adjunctive Treatment to Ziprasidone on Cognitive Deficits in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2007, 30, 3-12.	0.7	49
134	The Association Between Cognitive Functioning and Occupational Status in Persons With a Recent Onset of Psychosis. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 566-571.	1.0	19
135	Lamotrigine as Add-On Therapy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 582-589.	1.4	112
136	A Case-Control Study of Patients With Resistant Schizophrenia After Clozapine Discontinuation. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 90-91.	1.4	6
137	The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. <i>Psychological Medicine</i> , 2007, 37, 927-934.	4.5	79
138	Dissociation of cognitive from affective components of theory of mind in schizophrenia. <i>Psychiatry Research</i> , 2007, 149, 11-23.	3.3	315
139	Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1095-1100.	4.8	21
140	Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1504-1509.	4.8	31
141	Efficacité, efficence au long cours. <i>L'Encephale</i> , 2007, 33, 58-60.	0.9	1
143	The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 90, 186-197.	2.0	218
144	Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. <i>Schizophrenia Research</i> , 2007, 92, 90-94.	2.0	101
145	A prospective study of Quality of life in schizophrenia in three European countries. <i>Schizophrenia Research</i> , 2007, 93, 194-202.	2.0	61
146	Impairment in error monitoring predicts poor executive function in schizophrenia patients. <i>Schizophrenia Research</i> , 2007, 94, 156-163.	2.0	22
147	Social cognitive impairments in first episode psychosis. <i>Schizophrenia Research</i> , 2007, 95, 124-133.	2.0	111
148	NCAM1 and Neurocognition in Schizophrenia. <i>Biological Psychiatry</i> , 2007, 61, 902-910.	1.3	80
149	Schizophrenia: Measurements of Psychopathology. <i>Psychiatric Clinics of North America</i> , 2007, 30, 339-363.	1.3	24
150	Hoarding behaviour in Xhosa patients with schizophrenia - prevalence and clinical presentation. <i>South African Journal of Psychiatry</i> , 2007, 13, 4.	0.4	0
151	Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 602-609.	1.8	206

#	ARTICLE	IF	CITATIONS
152	Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. <i>Psychoneuroendocrinology</i> , 2007, 32, 385-391.	2.7	72
153	Alternative pathways to violence in persons with schizophrenia: The role of childhood antisocial behavior problems.. <i>Law and Human Behavior</i> , 2008, 32, 228-240.	0.7	179
154	Long-term effects of a community intervention for early identification of first-episode psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 440-448.	4.5	17
155	Suicidality prior to presentation in first-episode psychosis. <i>Microbial Biotechnology</i> , 2008, 2, 242-246.	1.7	27
156	Is facial emotion recognition impairment in schizophrenia identical for different emotions? A signal detection analysis. <i>Schizophrenia Research</i> , 2008, 99, 263-269.	2.0	77
157	Verbal as well as spatial working memory predicts visuospatial processing in male schizophrenia patients. <i>Schizophrenia Research</i> , 2008, 101, 210-217.	2.0	10
158	Sleep and Quality of Life in Clinical Medicine. , 2008, , .		32
159	Analysis of cognitive performance in schizophrenia patients and healthy individuals with unsupervised clustering models. <i>Psychiatry Research</i> , 2008, 159, 167-179.	3.3	34
160	The InterSePT suicide scale for prediction of imminent suicidal behaviors. <i>Psychiatry Research</i> , 2008, 161, 87-96.	3.3	18
161	Predictors of occupational status six months after hospitalization in persons with a recent onset of psychosis. <i>Psychiatry Research</i> , 2008, 160, 278-284.	3.3	44
162	Predictors of outcome three years after diagnosis of first episode psychosis. <i>Psychiatry Research</i> , 2008, 161, 11-18.	3.3	17
163	Effect of thought disorders on quality of life in patients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 332-335.	4.8	20
164	Investigating the neuropsychological and neuroanatomical changes that occur over the first 2-3 years of illness in patients with first-episode schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 531-538.	4.8	37
165	Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. <i>Comprehensive Psychiatry</i> , 2008, 49, 170-176.	3.1	45
166	Cognitive insight and verbal memory in first episode of psychosis. <i>European Psychiatry</i> , 2008, 23, 368-374.	0.2	69
167	Structural neural correlates of impairments in social cognition in first episode psychosis. <i>Social Neuroscience</i> , 2008, 3, 79-88.	1.3	31
168	Anhedonia and Social Adaptation Predict Substance Abuse Evolution in Dual Diagnosis Schizophrenia. <i>American Journal of Drug and Alcohol Abuse</i> , 2008, 34, 75-82.	2.1	17
169	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2008, 193, 37-43.	2.8	171

#	ARTICLE	IF	CITATIONS
170	Humour experience in schizophrenia: relationship with executive dysfunction and psychosocial impairment. <i>Psychological Medicine</i> , 2008, 38, 801-810.	4.5	40
171	rTMS strategies for the study and treatment of schizophrenia: a review. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 563-76.	2.1	33
172	Association of Physical and Social Anhedonia with Depression in the Acute Phase of Schizophrenia. <i>Psychopathology</i> , 2008, 41, 365-370.	1.5	29
173	Brain Magnetic Resonance Imaging in Newly Diagnosed Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 2348-2354.	2.0	70
174	Sleep and Quality of Life in Depression. , 2008, , 251-260.		1
175	Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S20-S28.	1.4	94
176	Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 978-987.	7.2	182
177	A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 465-472.	5.4	170
178	Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. <i>Journal of Psychopharmacology</i> , 2008, 22, 262-269.	4.0	45
179	Exploratory study of the association between insight and Theory of Mind (ToM) in stable schizophrenia patients. <i>Cognitive Neuropsychiatry</i> , 2008, 13, 210-232.	1.3	51
180	Affective modulation of external misattribution bias in source monitoring in schizophrenia. <i>Psychological Medicine</i> , 2008, 38, 821-824.	4.5	42
181	Depression in Schizophrenia: Methodological Artifact or Distinct Feature of the Illness?. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2008, 20, 431-440.	1.8	39
182	Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 985-97.	2.1	55
183	Correlates of Subjective Quality of Life in People With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 87-94.	1.0	83
184	Short-Term Testosterone Augmentation in Male Schizophrenics. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 375-383.	1.4	52
185	Suicide Risk in Schizophrenia, a 20 Year Cohort Study, Part 1: Outcome and associated social factors. <i>South African Journal of Psychiatry</i> , 2009, 15, 6.	0.4	0
186	Depression in Kraepelinian Schizophrenia. <i>South African Journal of Psychiatry</i> , 2009, 15, 4.	0.4	0
187	Combination therapy or monotherapy for the depressed type of schizoaffective disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 91.	2.2	4

#	ARTICLE	IF	CITATIONS
188	Suicide Risk in Schizophrenia - a follow-up study after 20 years. Part 2: Symptomatology and pharmacotherapy. South African Journal of Psychiatry, 2009, 15, 7.	0.4	0
189	Do patients with schizophrenia exhibit aberrant salience?. Psychological Medicine, 2009, 39, 199-209.	4.5	237
190	Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology, 2009, 34, 1885-1903.	5.4	168
191	Reliability and Validity of the Chinese Version of the Calgary Depression Scale for Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2009, 43, 548-553.	2.3	26
192	Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. Human Movement Science, 2009, 28, 633-642.	1.4	42
193	Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Human Psychopharmacology, 2009, 24, 565-573.	1.5	27
194	Anhedonia in schizophrenia and major depression: state or trait?. Annals of General Psychiatry, 2009, 8, 22.	2.7	182
195	Can targeted early intervention improve functional recovery in psychosis? A historical control evaluation of the effectiveness of different models of early intervention service provision in Norfolk 1998-2007. Microbial Biotechnology, 2009, 3, 282-288.	1.7	40
196	Exploring the role of face processing in facial emotion recognition in schizophrenia. Acta Neuropsychiatrica, 2009, 21, 292-300.	2.1	6
197	Clinical and serotonergic predictors of non-effective acute remitting psychosis in patients with a first-episode psychosis. Acta Psychiatrica Scandinavica, 2009, 119, 71-77.	4.5	10
198	Are symptoms associated with increased levels of perceived stress in first-episode psychosis?. International Journal of Mental Health Nursing, 2009, 18, 186-194.	3.8	14
199	Factors associated with functional psychosocial status in first-episode psychosis. Microbial Biotechnology, 2009, 3, 35-43.	1.7	5
200	Sociodemographic and clinical characteristics of patients presenting with first-episode psychosis and concurrent substance misuse. Microbial Biotechnology, 2009, 3, 75-79.	1.7	14
201	Quality of life and psychopathology during the course of schizophrenia. Comprehensive Psychiatry, 2009, 50, 542-548.	3.1	21
203	Schizophrenia with obsessive-compulsive disorder and obsessive-compulsive disorder with poor insight: A neuropsychological comparison. Psychiatry Research, 2009, 165, 38-46.	3.3	81
204	Impaired recognition of happy, sad and neutral expressions in schizophrenia is emotion, but not valence, specific and context dependent. Psychiatry Research, 2009, 169, 101-106.	3.3	39
205	No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 276-280.	4.8	20
206	Development and validation of a scale for assessing reasons for substance use in schizophrenia: The ReSUS scale. Addictive Behaviors, 2009, 34, 830-837.	3.0	24

#	ARTICLE	IF	CITATIONS
207	Does switching to a new antipsychotic improve outcomes?. Schizophrenia Research, 2009, 107, 22-29.	2.0	232
208	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research, 2009, 110, 80-89.	2.0	38
209	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research, 2009, 113, 112-121.	2.0	34
210	Motivational deficits as the central link to functioning in schizophrenia: A pilot study. Schizophrenia Research, 2009, 115, 333-337.	2.0	96
211	The CATIE and CUtLASS Studies in Schizophrenia. CNS Drugs, 2009, PAP, 649-59.	5.9	92
212	Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations.. Psychological Bulletin, 2009, 135, 157-171.	6.1	241
213	The Burden of Depressive Symptoms in People with Schizophrenia. Psychiatric Clinics of North America, 2009, 32, 853-861.	1.3	26
214	Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin, 2009, 35, 336-346.	4.3	228
215	Adult attachment, perceived earlier experiences of care giving and trauma in people with psychosis. Journal of Mental Health, 2009, 18, 280-287.	1.9	18
216	Scales for Evaluating Depressive Symptoms in Chinese Patients With Schizophrenia. Journal of Nervous and Mental Disease, 2009, 197, 140-142.	1.0	21
217	Early Predictors of Nonadherence to Antipsychotic Therapy in First-Episode Psychosis. Canadian Journal of Psychiatry, 2009, 54, 28-35.	1.9	74
218	Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia. Clinical Neuropharmacology, 2009, 32, 243-249.	0.7	40
219	Prevalence and clinical correlates of depression in the acute phase of first episode schizophrenia. Irish Journal of Psychological Medicine, 2010, 27, 15-18.	1.0	7
220	Esquire Trial. Journal of Clinical Psychopharmacology, 2010, 30, 600-606.	1.4	21
221	Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 106-115.	1.4	104
222	Depression and Depressive Symptoms in First Episode Psychosis. Journal of Nervous and Mental Disease, 2010, 198, 67-71.	1.0	70
223	Examination of Clinical and Cognitive Insight in Acute Schizophrenia Patients. Journal of Nervous and Mental Disease, 2010, 198, 465-469.	1.0	30
224	Factors Correlated With Client Attachment to Mental Health Services. Journal of Nervous and Mental Disease, 2010, 198, 572-575.	1.0	14

#	ARTICLE	IF	CITATIONS
225	Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia. Clinical Neuropharmacology, 2010, 33, 121-125.	0.7	28
226	Verbal Fluency in Schizophrenia. Journal of Nervous and Mental Disease, 2010, 198, 286-291.	1.0	43
227	Autobiographical Memory and Suicide Attempts in Schizophrenia. Suicide and Life-Threatening Behavior, 2010, 40, 369-375.	1.9	9
228	First episode psychosis and the trail to secondary care: help-seeking and health-system delays. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 381-391.	3.1	92
230	Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry, 2010, 10, 26.	2.6	53
231	A 12-month outcome study of insight and symptom change in first-episode psychosis. Microbial Biotechnology, 2010, 4, 79-88.	1.7	31
232	Family outcomes. , 2010, , 133-155.		0
233	Cost-effectiveness and cost-benefit analysis. , 2010, , 57-79.		0
234	Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. , 0, , 189-206.		4
235	Human subjects considerations. , 2010, , 255-266.		0
236	Antipsicóticos atípicos e comportamento suicida em pacientes esquizofrênicos ou esquizoafetivos. Revista De Psiquiatria Clinica, 2010, 37, 228-232.	0.6	1
237	Depression and Cognitive Impairment in Newly Diagnosed Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2032-2038.	2.0	98
238	A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 419-427.	4.3	73
239	Death by suicide long after electroconvulsive therapy. Is the sense of coherence test of Antonovsky a predictor of mortality from depression?. Mental Illness, 2010, 2, 11-15.	0.8	12
240	Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. Journal of Psychopharmacology, 2010, 24, 861-866.	4.0	60
241	Neurocognitive function in schizophrenia with comorbid posttraumatic stress disorder. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 737-751.	1.3	21
242	Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia. Journal of Psychopharmacology, 2010, 24, 83-89.	4.0	6
243	A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 937-952.	1.3	39

#	ARTICLE	IF	CITATIONS
244	Toward a Model of Cognitive Insight in First-Episode Psychosis: Verbal Memory and Hippocampal Structure. Schizophrenia Bulletin, 2010, 36, 1040-1049.	4.3	65
245	Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial. Schizophrenia Research, 2010, 116, 118-125.	2.0	16
246	Theory of Mind in first-episode schizophrenia patients: Correlations with cognition and personality traits. Schizophrenia Research, 2010, 119, 115-123.	2.0	119
247	Social functioning in urban, predominantly African American, socially disadvantaged patients with first-episode nonaffective psychosis. Schizophrenia Research, 2010, 119, 95-100.	2.0	13
248	Schizophrenia patients with polydipsia and water intoxication are characterized by greater severity of psychotic illness and a more frequent history of alcohol abuse. Schizophrenia Research, 2010, 118, 285-291.	2.0	27
249	Suicidality before and in the early phases of first episode psychosis. Schizophrenia Research, 2010, 119, 11-17.	2.0	91
250	Suicidality in first episode psychosis is associated with insight and negative beliefs about psychosis. Schizophrenia Research, 2010, 123, 257-262.	2.0	62
251	Slow wave sleep deficits as a trait marker in patients with schizophrenia. Schizophrenia Research, 2010, 124, 127-133.	2.0	51
252	Initial development and preliminary validation of a new negative symptom measure: The Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophrenia Research, 2010, 124, 36-42.	2.0	93
253	Progress in Defining Optimal Treatment Outcome in Schizophrenia. CNS Drugs, 2010, 24, 9-20.	5.9	74
254	Impact of panic attacks on quality of life among patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1300-1305.	4.8	11
255	SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1500-1506.	4.8	19
256	Relative contributions of psychotic symptoms and insight to quality of life in stable schizophrenia. Psychiatry Research, 2010, 177, 71-76.	3.3	19
257	Predictors of schizophrenia in patients with a first episode of psychosis. Psychiatry Research, 2010, 175, 11-14.	3.3	12
258	The use of screening instruments for detecting alcohol and other drug use disorders in first-episode psychosis. Psychiatry Research, 2010, 177, 228-234.	3.3	37
259	The effect of music on brain wave functioning during an acute psychotic episode: A pilot study. Psychiatry Research, 2010, 178, 446-448.	3.3	6
262	Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). European Neuropsychopharmacology, 2010, 20, 310-316.	0.7	53
263	Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla. Biological Psychiatry, 2011, 69, 19-27.	1.3	91

#	ARTICLE	IF	CITATIONS
264	A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. <i>Biological Psychiatry</i> , 2011, 69, 442-449.	1.3	155
265	Duration of untreated psychosis is associated with orbitalâ€“frontal grey matter volume reductions in first episode psychosis. <i>Schizophrenia Research</i> , 2011, 125, 13-20.	2.0	84
266	Folate supplementation in schizophrenia: A possible role for MTHFR genotype. <i>Schizophrenia Research</i> , 2011, 127, 41-45.	2.0	64
267	Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. <i>Schizophrenia Research</i> , 2011, 132, 101-107.	2.0	47
268	Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study. <i>Schizophrenia Research</i> , 2011, 130, 47-52.	2.0	28
269	Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits. <i>Schizophrenia Research</i> , 2011, 132, 24-27.	2.0	128
270	Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). <i>Schizophrenia Research</i> , 2011, 132, 140-145.	2.0	247
271	Substance use and schizophrenia: Adverse correlates in the CATIE study sample. <i>Schizophrenia Research</i> , 2011, 132, 177-182.	2.0	56
272	The Subjective Experiences of Psychosis Scale (SEPS): Psychometric evaluation of a scale to assess outcome in psychosis. <i>Schizophrenia Research</i> , 2011, 133, 244-249.	2.0	27
273	Effects of high aerobic intensity training in patients with schizophreniaâ€“A controlled trial. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 269-275.	1.3	105
274	Early intervention for psychosis. <i>The Cochrane Library</i> , 2011, , CD004718.	2.8	235
275	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in schizophrenic or schizoaffective patients. <i>European Psychiatry</i> , 2011, 26, 1415-1415.	0.2	2
276	Neurocognitive functioning and suicidality in schizophrenia spectrum disorders. <i>Comprehensive Psychiatry</i> , 2011, 52, 156-163.	3.1	49
277	Straight gyrus morphology in first-episode schizophrenia-spectrum patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 84-90.	4.8	4
278	Sex-specific cortisol levels in bipolar disorder and schizophrenia during mental challenge â€“ Relationship to clinical characteristics and medication. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1100-1107.	4.8	27
279	Cognitionâ€“UPSA score relationships: A further analysis of Silverstein et al. (2010) data and some caveats. <i>Psychiatry Research</i> , 2011, 187, 424-431.	3.3	10
280	Anticipatory vs. consummatory pleasure: What is the nature of hedonic deficits in schizophrenia?. <i>Psychiatry Research</i> , 2011, 187, 36-41.	3.3	122
281	Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia. <i>Psychiatry Research</i> , 2011, 189, 43-48.	3.3	66

#	ARTICLE	IF	CITATIONS
283	Assessment of Social Anxiety in First Episode Psychosis using the Liebowitz Social Anxiety scale as a Self-report Measure. <i>European Psychiatry</i> , 2011, 26, 115-121.	0.2	25
284	Cannabis use predicts shorter duration of untreated psychosis and lower levels of negative symptoms in first-episode psychosis: a South African study. <i>African Journal of Psychiatry</i> , 2011, 13, 395-9.	0.1	10
285	Criterion and Construct Validity of the CogState Schizophrenia Battery in Japanese Patients with Schizophrenia. <i>PLoS ONE</i> , 2011, 6, e20469.	2.5	34
286	Switching from Quetiapine to Ziprasidone. <i>Journal of Psychiatric Practice</i> , 2011, 17, 100-109.	0.7	15
287	Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2011, 26, 303-310.	1.7	34
288	Predicting Psychiatric Hospital Admission Among Adults With Schizophrenia. <i>Psychiatric Services</i> , 2011, 62, 1138-1145.	2.0	51
289	Psychopathological and Functional Correlates of Behavioral Activation and Avoidance in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 861-865.	1.0	10
291	Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 228-238.	4.5	45
292	Exposure to trauma and the clinical presentation of first-episode psychosis in South Africa. <i>Journal of Psychiatric Research</i> , 2011, 45, 179-184.	3.1	22
293	Cortical thickness is associated with poor insight in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2011, 45, 781-787.	3.1	51
294	Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. <i>Journal of Psychiatric Research</i> , 2011, 45, 1381-1386.	3.1	62
295	Adjunct Mirtazapine for Negative Symptoms of Schizophrenia. <i>Pharmacotherapy</i> , 2011, 31, 1017-1030.	2.6	16
296	Quantifying Clinical Relevance in the Treatment of Schizophrenia. <i>Clinical Therapeutics</i> , 2011, 33, B16-B39.	2.5	94
297	Effect of Serotonin-Related Gene Polymorphisms on Pathogenesis and Treatment Response in Korean Schizophrenic Patients. <i>Behavior Genetics</i> , 2011, 41, 709-715.	2.1	19
298	Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression. <i>EPMA Journal</i> , 2011, 2, 391-402.	6.1	6
299	Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. <i>BMC Psychiatry</i> , 2011, 11, 145.	2.6	26
300	Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia. <i>International Journal of Methods in Psychiatric Research</i> , 2011, 20, e31-e37.	2.1	20
301	Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3048-3057.	6.7	55

#	ARTICLE	IF	CITATIONS
302	High-Frequency Prefrontal Repetitive Transcranial Magnetic Stimulation for the Negative Symptoms of Schizophrenia. <i>Journal of ECT</i> , 2011, 27, 11-17.	0.6	15
303	Causal attributions, pathway to care and clinical features of first-episode psychosis: A South African perspective. <i>International Journal of Social Psychiatry</i> , 2011, 57, 538-545.	3.1	57
304	The Negative Symptoms of Schizophrenia: Category or Continuum?. <i>Psychopathology</i> , 2011, 44, 345-353.	1.5	68
305	Sexual Dysfunction and Hyperprolactinemia in Male Psychotic Inpatients: A Cross-Sectional Study. <i>Advances in Urology</i> , 2011, 2011, 1-6.	1.3	11
306	Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 192-202.	1.3	7
307	The role of defeat and entrapment in depression, anxiety, and suicide.. <i>Psychological Bulletin</i> , 2011, 137, 391-420.	6.1	286
308	Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. <i>Journal of Psychopharmacology</i> , 2012, 26, 1194-1200.	4.0	10
309	Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2012, 27, 267-274.	1.7	28
310	Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 36-45.	1.4	54
311	Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 95-99.	1.4	22
312	Role of the Self in Schizophrenia: A Multidimensional Examination of Short-Term Outcomes. <i>Psychiatry (New York)</i> , 2012, 75, 285-297.	0.7	21
313	Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. <i>Psychopathology</i> , 2012, 45, 276-285.	1.5	46
314	Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. <i>Translational Psychiatry</i> , 2012, 2, e128-e128.	4.8	42
315	Guide to Assessment Scales in Schizophrenia. , 2012, , .		5
316	Antipsychotic agents: efficacy and safety in schizophrenia. <i>Drug, Healthcare and Patient Safety</i> , 2012, 4, 173.	2.5	18
317	Selective Aggregation of Self-Disorders in First-Treatment DSM-IV Schizophrenia Spectrum Disorders. <i>Journal of Nervous and Mental Disease</i> , 2012, 200, 632-636.	1.0	98
318	Parsing the components of the psychomotor syndrome in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 256-265.	4.5	79
319	Auditory stream segregation impairments in schizophrenia. <i>Psychophysiology</i> , 2012, 49, 1372-1383.	2.4	16

#	ARTICLE	IF	CITATIONS
320	A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia. Schizophrenia Research, 2012, 142, 145-152.	2.0	69
321	Pimavanserin, a selective serotonin (5-HT) _{2A} -inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. Schizophrenia Research, 2012, 141, 144-152.	2.0	87
322	Neurological soft signs in schizophrenia and obsessive compulsive disorder spectrum. European Psychiatry, 2012, 27, 192-199.	0.2	24
323	Symptom Attribution in first episode psychosis: A cortical thickness study. Psychiatry Research - Neuroimaging, 2012, 203, 6-13.	1.8	37
324	Predictors of antipsychotic dose changes in the CATIE schizophrenia trial. Psychiatry Research, 2012, 199, 1-7.	3.3	9
325	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naïve patients with a first-episode psychosis. Psychiatry Research, 2012, 200, 693-701.	3.3	29
326	Impact of symptom resolution on medication adherence in first episode psychosis. Psychiatry Research, 2012, 196, 45-51.	3.3	16
327	Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Comprehensive Psychiatry, 2012, 53, 145-151.	3.1	90
328	Depression and quality of life in first-episode psychosis. Comprehensive Psychiatry, 2012, 53, 451-455.	3.1	40
329	The association between anomalous self-experience and suicidality in first-episode schizophrenia seems mediated by depression. Comprehensive Psychiatry, 2012, 53, 456-460.	3.1	42
330	A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Services Research, 2012, 12, 269-76.	2.2	21
331	Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia. Comprehensive Psychiatry, 2012, 53, 1137-1144.	3.1	87
332	Depression and cognitive deficits in geriatric schizophrenia. Schizophrenia Research, 2012, 134, 65-69.	2.0	12
333	Adjunctive armodafinil for negative symptoms in adults with schizophrenia: A double-blind, placebo-controlled study. Schizophrenia Research, 2012, 135, 116-122.	2.0	23
334	Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed. Schizophrenia Research, 2012, 135, 72-78.	2.0	72
335	Screening and assessing ideas and delusions of reference using a semi-structured interview scale: A validation study of the Ideas of Reference Interview Scale (IRIS) in early psychosis patients. Schizophrenia Research, 2012, 135, 158-163.	2.0	27
336	Screening for negative symptoms: Preliminary results from the self-report version of the Clinical Assessment Interview for Negative Symptoms. Schizophrenia Research, 2012, 135, 139-143.	2.0	34
337	Computerized cognitive remediation training for schizophrenia: An open label, multi-site, multinational methodology study. Schizophrenia Research, 2012, 139, 87-91.	2.0	77

#	ARTICLE	IF	CITATIONS
338	Diffusion tensor imaging tractography of the fornix and belief confidence in first-episode psychosis. Schizophrenia Research, 2012, 137, 80-84.	2.0	24
339	The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry, 2012, 12, 172.	2.6	161
340	Social capital, pathway to care and duration of untreated psychosis: Findings from a low- and middle-income country context. South African Journal of Psychiatry, 2012, 18, 8.	0.4	3
341	Depression and schizophrenia. Advances in Psychiatric Treatment, 2012, 18, 280-288.	0.5	9
342	Service user attachments to psychiatric key workers and teams. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 817-825.	3.1	13
343	Processing speed and executive functions predict real-world everyday living skills in adolescents with early-onset schizophrenia. European Child and Adolescent Psychiatry, 2012, 21, 315-326.	4.7	30
344	A comparison of correlates of suicidal ideation prior to initial hospitalization for first-episode psychosis with prior research on correlates of suicide attempts prior to initial treatment seeking. Microbial Biotechnology, 2012, 6, 138-144.	1.7	18
345	Group cognitive behavioural therapy for first episode psychosis: who's referred, who attends and who completes it?. Microbial Biotechnology, 2012, 6, 432-441.	1.7	26
346	Detection of people at risk of developing a first psychosis: comparison of two recruitment strategies. Acta Psychiatrica Scandinavica, 2012, 126, 21-30.	4.5	71
347	Suicide ideators and attempters with schizophrenia – The role of 5-HTTLPR, rs25531, and 5-HTT VNTR Intron 2 variants. Journal of Psychiatric Research, 2012, 46, 767-773.	3.1	19
348	Acquired self-control of insula cortex modulates emotion recognition and brain network connectivity in schizophrenia. Human Brain Mapping, 2013, 34, 200-212.	3.6	242
349	Depressive symptoms in first episode psychosis: a one-year follow-up study. BMC Psychiatry, 2013, 13, 106.	2.6	44
350	The extent and origin of discordance between self- and observer-rated depression in patients with psychosis. Psychiatry Research, 2013, 205, 247-252.	3.3	11
351	Affective Instability Prior to and after Thoughts about Self-Injury in Individuals With and At-Risk of Psychosis: A Mobile Phone Based Study. Archives of Suicide Research, 2013, 17, 275-287.	2.3	18
352	Neuronal correlates of appetite regulation in patients with schizophrenia: Is there a basis for future appetite dysfunction?. European Psychiatry, 2013, 28, 293-301.	0.2	7
353	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46
354	Haloperidol versus placebo for schizophrenia. The Cochrane Library, 2013, , CD003082.	2.8	60
355	A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophrenia Research, 2013, 143, 138-142.	2.0	61

#	ARTICLE	IF	CITATIONS
356	The use of the Theory of Planned Behavior to predict engagement in functional behaviors in schizophrenia. <i>Psychiatry Research</i> , 2013, 205, 36-42.	3.3	16
357	Assessment of real-world daily-living skills in early-onset schizophrenia through the Life Skills Profile scale. <i>Schizophrenia Research</i> , 2013, 145, 95-100.	2.0	9
358	Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. <i>Journal of Psychiatric Research</i> , 2013, 47, 1590-1596.	3.1	177
359	A detailed analysis of the effect of repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: A double-blind trial. <i>Schizophrenia Research</i> , 2013, 149, 167-173.	2.0	54
360	Perceived Stigma Exposure in Schizophrenia: The Key Role of Self-concept Clarity. <i>Self and Identity</i> , 2013, 12, 663-674.	1.6	18
361	Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 46, 25-28.	4.8	21
362	Multimodal neuroimaging of frontal white matter microstructure in early phase schizophrenia: the impact of early adolescent cannabis use. <i>BMC Psychiatry</i> , 2013, 13, 264.	2.6	8
363	Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. <i>BMC Psychiatry</i> , 2013, 13, 241.	2.6	10
364	Suicide attempts in schizophrenic patients: Clinical variables. <i>Asian Journal of Psychiatry</i> , 2013, 6, 421-427.	2.0	24
365	Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study. <i>Schizophrenia Research</i> , 2013, 151, 203-208.	2.0	35
366	Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data. <i>Schizophrenia Research</i> , 2013, 150, 373-379.	2.0	8
367	Internalized stigma in schizophrenia: Relations with dysfunctional attitudes, symptoms, and quality of life. <i>Psychiatry Research</i> , 2013, 205, 43-47.	3.3	77
368	Validation of an abbreviated quality of life scale for schizophrenia. <i>European Neuropsychopharmacology</i> , 2013, 23, 1072-1077.	0.7	14
369	Blunted cortisol awakening response in men with first episode psychosis: Relationship to parental bonding. <i>Psychoneuroendocrinology</i> , 2013, 38, 229-240.	2.7	52
370	The Longitudinal Youth at Risk Study (LYRIKS) – An Asian UHR perspective. <i>Schizophrenia Research</i> , 2013, 151, 279-283.	2.0	46
371	Amotivation and functional outcomes in early schizophrenia. <i>Psychiatry Research</i> , 2013, 210, 665-668.	3.3	69
372	Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes. <i>British Journal of Psychiatry</i> , 2013, 203, 215-220.	2.8	12
373	Depression and social anxiety in help-seeking patients with an ultra-high risk for developing psychosis. <i>Psychiatry Research</i> , 2013, 209, 309-313.	3.3	55

#	ARTICLE	IF	CITATIONS
374	Decreased fMRI activity in the hippocampus of patients with schizophrenia compared to healthy control participants, tested on a wayfinding task in a virtual town. <i>Psychiatry Research - Neuroimaging</i> , 2013, 211, 47-56.	1.8	34
375	The Motivation and Pleasure Scale—Self-Report (MAP-SR): Reliability and validity of a self-report measure of negative symptoms. <i>Comprehensive Psychiatry</i> , 2013, 54, 568-574.	3.1	142
376	Verbal learning and memory and psychopathology in schizophrenia. <i>Asian Journal of Psychiatry</i> , 2013, 6, 417-420.	2.0	10
377	Reduced expression of SP1 and SP4 transcription factors in peripheral blood mononuclear cells in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2013, 47, 1608-1614.	3.1	27
378	Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. <i>Schizophrenia Research</i> , 2013, 143, 207-214.	2.0	31
379	Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-7.	1.5	6
380	Are there differential deficits in facial emotion recognition between paranoid and non-paranoid schizophrenia? A signal detection analysis. <i>Psychiatry Research</i> , 2013, 209, 424-430.	3.3	14
381	Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 61-91.	3.1	22
382	Direct and mediated effects of cognitive function with multidimensional outcome measures in schizophrenia: The role of functional capacity. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 882-895.	1.3	9
383	The Clinical Assessment Interview for Negative Symptoms (CAINS): Final Development and Validation. <i>American Journal of Psychiatry</i> , 2013, 170, 165-172.	7.2	559
384	Comparison of Outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE Study. <i>Psychiatric Services</i> , 2013, 64, 570-578.	2.0	12
385	Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. <i>Neuropsychopharmacology</i> , 2013, 38, 492-503.	5.4	67
386	QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-7.	1.5	7
387	Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases. <i>Neuropsychopharmacology</i> , 2013, 38, 2140-2149.	5.4	36
388	Rorschach measures of cognition relate to everyday and social functioning in schizophrenia.. <i>Psychological Assessment</i> , 2013, 25, 253-263.	1.5	24
389	Suicidal ideation among a group of Kurdish schizophrenic patients. <i>Middle East Current Psychiatry</i> , 2013, 20, 229-234.	1.2	0
390	Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. <i>International Clinical Psychopharmacology</i> , 2013, 28, 46-49.	1.7	31
391	Using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Effort Index to Predict Treatment Group Attendance in Patients with Schizophrenia. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 198-205.	1.8	19

#	ARTICLE	IF	CITATIONS
392	Sleep dysfunction prior to the onset of schizophrenia: A review and neurodevelopmental diathesis-stress conceptualization.. <i>Clinical Psychology: Science and Practice</i> , 2013, 20, 291-320.	0.9	50
393	Is there an optimal factor structure of the Positive and Negative Syndrome Scale in patients with first-episode psychosis?. <i>Scandinavian Journal of Psychology</i> , 2013, 54, 160-165.	1.5	51
394	Schizophrenia patients with and without Post-traumatic Stress Disorder (<scp>PTSD</scp>) have different mood symptom levels but same cognitive functioning. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 455-463.	4.5	13
395	Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study. <i>Schizophrenia Bulletin</i> , 2013, 39, 993-998.	4.3	92
396	Haloperidol dose for the acute phase of schizophrenia. <i>The Cochrane Library</i> , 2013, , CD001951.	2.8	20
397	Assessment of depression in medical patients: A systematic review of the utility of the Beck Depression Inventory-II. <i>Clinics</i> , 2013, 68, 1274-1287.	1.5	194
398	Reliability and validity of the Thai version of the Calgary Depression Scale for Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 113.	2.2	8
399	Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 661.	2.0	66
400	Variables Influencing Subjective Well-Being in Patients with Schizophrenia. <i>Korean Journal of Schizophrenia Research</i> , 2014, 17, 93.	0.3	0
401	Increased Prolactin Levels Are Associated with Impaired Processing Speed in Subjects with Early Psychosis. <i>PLoS ONE</i> , 2014, 9, e89428.	2.5	33
402	Impact of Substance Use Disorder on Presentation and Short-Term Course of Schizophrenia. <i>Psychiatry Journal</i> , 2014, 2014, 1-9.	1.5	9
403	Structural Hippocampal Anomalies in a Schizophrenia Population Correlate with Navigation Performance on a Wayfinding Task. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 88.	2.0	20
404	Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review. <i>Journal of Huntington's Disease</i> , 2014, 3, 233-252.	1.9	25
405	Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. <i>CNS Spectrums</i> , 2014, 19, 330-339.	1.2	38
406	A Mixed-Methods Evaluation of a Pilot Psychosocial Intervention Group for Older People with Schizophrenia. <i>Behavioural and Cognitive Psychotherapy</i> , 2014, 42, 199-210.	1.2	6
407	Loneliness mediates the relationship between internalised stigma and depression among patients with psychotic disorders. <i>International Journal of Social Psychiatry</i> , 2014, 60, 733-740.	3.1	38
408	Perfectionistic Self-Presentation and Suicide in a Young Woman with Major Depression and Psychotic Features. <i>Case Reports in Psychiatry</i> , 2014, 2014, 1-6.	0.5	7
409	The Temporal Association Between Self-Injurious Thoughts and Psychotic Symptoms: A Mobile Phone Assessment Study. <i>Suicide and Life-Threatening Behavior</i> , 2014, 44, 101-110.	1.9	13

#	ARTICLE	IF	CITATIONS
410	Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 290-299.	4.5	190
411	Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. <i>Human Psychopharmacology</i> , 2014, 29, 483-491.	1.5	60
412	Validity of subjective versus objective quality of life assessment in people with schizophrenia. <i>BMC Psychiatry</i> , 2014, 14, 365.	2.6	47
413	Selective Effect of Neurocognition on Different Theory of Mind Domains in First-Episode Psychosis. <i>Journal of Nervous and Mental Disease</i> , 2014, 202, 576-582.	1.0	20
414	Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 682-689.	1.4	11
415	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia. <i>International Clinical Psychopharmacology</i> , 2014, 29, 166-176.	1.7	9
416	Motivational Deficits and Cognitive Test Performance in Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1058.	11.0	122
417	The Glutamate Hypothesis: A Pathogenic Pathway from which Pharmacological Interventions have Emerged. <i>Pharmacopsychiatry</i> , 2014, 47, 121-130.	3.3	30
418	An exploration of the therapeutic alliance within a telephone-based cognitive behaviour therapy for individuals with experience of psychosis. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2014, 87, 393-410.	2.5	22
419	Altered systemic cortisol metabolism in bipolar disorder and schizophrenia spectrum disorders. <i>Journal of Psychiatric Research</i> , 2014, 52, 57-62.	3.1	36
420	Relatives' illness attributions mediate the association of expressed emotion with early psychosis symptoms and functioning. <i>Psychiatry Research</i> , 2014, 218, 48-53.	3.3	24
421	Converting positive and negative symptom scores between PANSS and SAPS/SANS. <i>Schizophrenia Research</i> , 2014, 152, 289-294.	2.0	111
422	Psychometric properties of the Questionnaire about the Process of Recovery (QPR). <i>Schizophrenia Research</i> , 2014, 156, 184-189.	2.0	107
423	Negative symptoms and everyday functioning in schizophrenia: A cross-sectional study in a real world-setting. <i>Psychiatry Research</i> , 2014, 218, 284-289.	3.3	82
424	History of Religious Delusions and Psychosocial Functioning Among Mexican Patients with Paranoid Schizophrenia. <i>Journal of Religion and Health</i> , 2014, 53, 1622-1633.	1.7	6
425	Toward a more parsimonious assessment of neurocognition in schizophrenia: A 10-minute assessment tool. <i>Journal of Psychiatric Research</i> , 2014, 52, 50-56.	3.1	25
426	The impact of alcohol on clinical outcomes in established psychosis: a longitudinal study. <i>Addiction</i> , 2014, 109, 1297-1305.	3.3	10
427	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 478-486.	2.0	33

#	ARTICLE	IF	CITATIONS
428	Schizophrenia miR-137 Locus Risk Genotype Is Associated with Dorsolateral Prefrontal Cortex Hyperactivation. <i>Biological Psychiatry</i> , 2014, 75, 398-405.	1.3	65
429	The nature of the relationship of psychomotor slowing with negative symptomatology in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2014, 19, 36-46.	1.3	39
430	Neural processing of facial expressions of emotion in first onset psychosis. <i>Psychiatry Research</i> , 2014, 219, 477-485.	3.3	20
431	A systematic review of evidence-based treatment for individuals with treatment-resistant schizophrenia and a suboptimal response to clozapine monotherapy. <i>Psychosis</i> , 2014, 6, 253-265.	0.8	6
432	Relative contributions of negative symptoms, insight, and coping strategies to quality of life in stable schizophrenia. <i>Psychiatry Research</i> , 2014, 220, 102-111.	3.3	30
433	Metacognitive training for schizophrenia: A multicentre randomised controlled trial. <i>Schizophrenia Research</i> , 2014, 157, 99-106.	2.0	51
434	Cognitive Remediation Therapy in Adolescents With Early-Onset Schizophrenia: A Randomized Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 859-868.	0.5	57
435	Evaluation of Different Approaches for Confounding in Nonrandomised Observational Data: A Case-Study of Antipsychotics Treatment. <i>Community Mental Health Journal</i> , 2014, 50, 711-720.	2.0	1
436	Anomalous self-experiences contribute independently to social dysfunction in the early phases of schizophrenia and psychotic bipolar disorder. <i>Comprehensive Psychiatry</i> , 2014, 55, 475-482.	3.1	45
437	One year follow-up of alcohol and illicit substance use in first-episode psychosis: Does gender matter?. <i>Comprehensive Psychiatry</i> , 2014, 55, 274-282.	3.1	34
438	Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2014, 153, 64-67.	2.0	76
439	Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study. <i>European Neuropsychopharmacology</i> , 2014, 24, 1078-1085.	0.7	21
440	Impact of primary negative symptoms on functional outcomes in schizophrenia. <i>European Psychiatry</i> , 2014, 29, 449-455.	0.2	153
441	Daily activity patterns in remitted first-episode schizophrenia. <i>Comprehensive Psychiatry</i> , 2014, 55, 1182-1187.	3.1	7
442	Cognitive Behavior Therapy in First-Episode Psychosis With a Focus on Depression, Anxiety, and Self-Esteem. <i>Cognitive and Behavioral Practice</i> , 2014, 21, 43-54.	1.5	7
443	Abbreviated quality of life scales for schizophrenia: Comparison and utility of two brief community functioning measures. <i>Schizophrenia Research</i> , 2014, 154, 89-92.	2.0	15
444	Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. <i>European Psychiatry</i> , 2014, 29, 191-196.	0.2	40
445	The cognitive behavioural prevention of suicide in psychosis: A clinical trial. <i>Schizophrenia Research</i> , 2014, 156, 204-210.	2.0	65

#	ARTICLE	IF	CITATION
446	Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophrenia Research, 2014, 156, 254-260.	2.0	22
447	Social class mobility in first episode psychosis and the association with depression, hopelessness and suicidality. Schizophrenia Research, 2014, 157, 8-11.	2.0	9
448	Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectrums, 2014, 19, 316-323.	1.2	34
449	Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. International Journal of Neuropsychopharmacology, 2014, 17, 343-354.	2.1	25
450	Motivation and Social Cognition in Patients with Schizophrenia. Journal of the International Neuropsychological Society, 2015, 21, 436-443.	1.8	16
451	Negative symptoms in schizophrenia show association with amygdala volumes and neural activation during affective processing. Acta Neuropsychiatrica, 2015, 27, 213-220.	2.1	31
452	NB-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Movement Disorders, 2015, 30, 1681-1687.	3.9	105
454	Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial. Trials, 2015, 16, 404.	1.6	38
455	Yoga versus standard care for schizophrenia. The Cochrane Library, 2015, 2015, CD010554.	2.8	32
456	Subjective quality of life in <sc>A</sc>-<sc>R</sc>-<sc>M</sc>-<sc>S</sc>-state for psychosis patients: relationship with symptom severity and functional impairment. Microbial Biotechnology, 2015, 9, 292-299.	1.7	18
457	Resting State Dense Array Gamma Oscillatory Activity as a Response Marker for Cerebellar-Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia. Journal of ECT, 2015, 31, 258-262.	0.6	25
458	The RAISE Connection Program for Early Psychosis. Journal of Nervous and Mental Disease, 2015, 203, 365-371.	1.0	30
459	Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. Journal of Nervous and Mental Disease, 2015, 203, 486-492.	1.0	16
460	Gender Differences in the Formal Thought Disorder in Patients with Schizophrenia. Journal of Korean Neuropsychiatric Association, 2015, 54, 291.	0.5	0
461	Symptomatic Conceptualization of Disorganized Speech in Patients with Schizophrenia. Korean Journal of Schizophrenia Research, 2015, 18, 51.	0.3	3
462	Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. Frontiers in Human Neuroscience, 2015, 9, 234.	2.0	97
463	Treating Depressive Symptoms in Psychosis: A Network Meta-Analysis on the Effects of Non-Verbal Therapies. PLoS ONE, 2015, 10, e0140637.	2.5	5
464	Motivational deficits in early schizophrenia: Prevalent, persistent, and key determinants of functional outcome. Schizophrenia Research, 2015, 166, 9-16.	2.0	120

#	ARTICLE	IF	CITATIONS
465	Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis. Schizophrenia Research, 2015, 166, 37-42.	2.0	21
466	Insight and illness perception in Mexican patients with psychosis. Schizophrenia Research: Cognition, 2015, 2, 33-38.	1.3	2
467	Management of Depressive Symptoms in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2015, 9, 13-20.	1.4	7
468	Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophrenia. Psychiatry Research, 2015, 230, 860-866.	3.3	29
469	Effects of high-intensity aerobic exercise on psychotic symptoms and neurocognition in outpatients with schizophrenia: study protocol for a randomized controlled trial. Trials, 2015, 16, 557.	1.6	22
470	Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?. Journal of Dual Diagnosis, 2015, 11, 153-160.	1.2	19
471	Apathy But Not Diminished Expression in Schizophrenia Is Associated With Discounting of Monetary Rewards by Physical Effort. Schizophrenia Bulletin, 2015, 41, 503-512.	4.3	161
472	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophrenia Research, 2015, 161, 351-356.	2.0	32
473	Reduced hippocampal volume and hypothalamusâ€“pituitaryâ€“adrenal axis function in first episode psychosis: Evidence for sex differences. Neurolmage: Clinical, 2015, 7, 195-202.	2.7	43
474	Compensatory cognitive training for people with first-episode schizophrenia: Results from a pilot randomized controlled trial. Schizophrenia Research, 2015, 162, 108-111.	2.0	50
475	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. Schizophrenia Research, 2015, 161, 429-433.	2.0	22
476	Preliminary evidence for reduced auditory lateral suppression in schizophrenia. Schizophrenia Research, 2015, 162, 269-275.	2.0	2
477	Is good insight associated with depression among patients with schizophrenia? Systematic review and meta-analysis. Schizophrenia Research, 2015, 162, 234-247.	2.0	98
478	What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?. European Psychiatry, 2015, 30, 43-50.	0.2	18
479	Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. European Neuropsychopharmacology, 2015, 25, 295-302.	0.7	8
481	Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis. International Journal of Neuropsychopharmacology, 2015, 18, pyu042-pyu042.	2.1	77
482	Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 259-268.	3.2	38
483	Increased visual gamma power in schizoaffective bipolar disorder. Psychological Medicine, 2015, 45, 783-794.	4.5	16

#	ARTICLE	IF	CITATIONS
484	Anhedonia in schizophrenia: The role of subjective experiences. <i>Comprehensive Psychiatry</i> , 2015, 62, 152-160.	3.1	21
485	Reliability and validity of the Korean version of the Scale for the Assessment of Thought, Language, and Communication. <i>Comprehensive Psychiatry</i> , 2015, 61, 122-130.	3.1	10
486	Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis. <i>Schizophrenia Research</i> , 2015, 166, 225-230.	2.0	34
487	Meta-cognition is associated with cortical thickness in youth at clinical high risk of psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2015, 233, 418-423.	1.8	19
488	Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS). <i>Schizophrenia Research</i> , 2015, 166, 104-109.	2.0	50
489	Childhood abuse and neglect in relation to the presence and persistence of psychotic and depressive symptomatology. <i>Psychological Medicine</i> , 2015, 45, 1363-1377.	4.5	86
490	Motivated to do well: An examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 276-282.	2.0	57
491	Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an ± 7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. <i>Neuropsychopharmacology</i> , 2015, 40, 3053-3060.	5.4	120
492	High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. <i>Psychiatry Research</i> , 2015, 229, 295-301.	3.3	47
493	Insight and subjective measures of quality of life in chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 127-132.	1.3	47
494	Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. <i>Journal of Psychiatric Research</i> , 2015, 68, 210-216.	3.1	51
495	A new computerized cognitive and social cognition training specifically designed for patients with schizophrenia/schizoaffective disorder in early stages of illness: A pilot study. <i>Psychiatry Research</i> , 2015, 228, 501-509.	3.3	35
496	Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis “ Findings from the Longitudinal Youth at Risk Study (LYRIKS). <i>Schizophrenia Research</i> , 2015, 164, 8-14.	2.0	94
497	Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. <i>Schizophrenia Research</i> , 2015, 164, 149-154.	2.0	12
498	Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. <i>Psychiatry Research</i> , 2015, 226, 368-375.	3.3	16
499	Effects of depression on the cytokine profile in drug naïve first-episode psychosis. <i>Schizophrenia Research</i> , 2015, 164, 53-58.	2.0	48
500	Self-harm in schizophrenia is associated with dorsolateral prefrontal and posterior cingulate activity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 61, 18-23.	4.8	13
501	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Schizophrenia Bulletin</i> , 2015, 41, 549-558.	4.3	47

#	ARTICLE	IF	CITATIONS
502	The development of insight and its relationship with suicidality over one year follow-up in patients with first episode psychosis. Schizophrenia Research, 2015, 162, 97-102.	2.0	42
503	Clinical and Functional Outcomes in People With Schizophrenia With a High Sense of Well-Being. Journal of Nervous and Mental Disease, 2015, 203, 187-193.	1.0	10
504	Treatment of depressive symptoms in patients with schizophrenia. International Clinical Psychopharmacology, 2015, 30, 14-22.	1.7	8
505	The course of negative symptoms over the first five years of treatment: Data from an early intervention program for psychosis. Schizophrenia Research, 2015, 169, 412-417.	2.0	19
506	Clinical correlates of obsessive-compulsive symptom dimensions in at-risk mental states and psychotic disorders at early stages. Psychiatry Research, 2015, 228, 363-367.	3.3	10
507	The sense of empowerment in the early stage of recovery from psychosis. Psychosis, 2015, 7, 249-260.	0.8	9
508	Suicidality in Schizophrenia Spectrum Disorders: The Relationship to Hallucinations and Persecutory Delusions. European Psychiatry, 2015, 30, 830-836.	0.2	77
509	Social affiliation and negative symptoms in schizophrenia: Examining the role of behavioral skills and subjective responding. Schizophrenia Research, 2015, 168, 491-497.	2.0	52
510	Insight, Stigma et Auto-stigmatisation: lâ€™intime conviction appliqu�e aux patients schizophr�nes hospitalis�s au sein d�un h�pital psychiatrique s�curis�. Annales Medico-Psychologiques, 2015, 173, 913-915.	0.4	2
511	Patients' subjective rating of mental health improvement in a randomised controlled trial. Psychiatry Research, 2015, 229, 593-595.	3.3	5
512	Rate and risk factors of depressive symptoms in Chinese patients presenting with first-episode non-affective psychosis in Hong Kong. Schizophrenia Research, 2015, 168, 99-105.	2.0	24
513	Correlation between neuropsychological and social cognition measures and symptom dimensions in schizophrenic patients. Psychiatry Research, 2015, 230, 172-180.	3.3	16
514	The stages of recovery in relation to the other subjective and objective aspects of psychosis. Psychiatry Research, 2015, 225, 613-618.	3.3	9
515	Anomalous self-experience and childhood trauma in first-episode schizophrenia. Comprehensive Psychiatry, 2015, 56, 35-41.	3.1	43
516	Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia. Schizophrenia Bulletin, 2015, 41, 900-908.	4.3	17
517	Could the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) be used in depressed schizophrenia patients?. Journal of Affective Disorders, 2015, 172, 191-194.	4.1	9
518	Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 3221-3236.	2.2	14
519	Measuring negative symptoms in patients with schizophrenia: reliability and validity of the Korean version of the Motivation and Pleasure Scale-Self-Report. Neuropsychiatric Disease and Treatment, 2016, 12, 1167.	2.2	8

#	ARTICLE	IF	CITATIONS
520	Factors Predicting Personal and Social Performance in Schizophrenia Patients. Korean Journal of Schizophrenia Research, 2016, 19, 47.	0.3	3
521	Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. Trends in Psychiatry and Psychotherapy, 2016, 38, 175-177.	0.8	20
522	MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study). International Journal of Molecular Sciences, 2016, 17, 1075.	4.1	10
523	The Association between Anomalous Self-experiences, Self-esteem and Depressive Symptoms in First Episode Schizophrenia. Frontiers in Human Neuroscience, 2016, 10, 557.	2.0	12
524	Confirmatory Factor Analysis and Differential Relationships of the Two Subdomains of Negative Symptoms in Chronically Ill Psychotic Patients. PLoS ONE, 2016, 11, e0149785.	2.5	31
525	Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. PLoS ONE, 2016, 11, e0143490.	2.5	52
526	A Low-Intensity Mindfulness-Based Intervention for Mood Symptoms in People with Early Psychosis: Development and Pilot Evaluation. Clinical Psychology and Psychotherapy, 2016, 23, 550-560.	2.7	21
527	Hypothalamic-pituitary-adrenal axis measures and cognitive abilities in early psychosis: Are there sex differences?. Psychoneuroendocrinology, 2016, 72, 54-62.	2.7	17
528	History of psychosis and previous episodes as potential explanatory factors for neurocognitive impairment in first-treatment bipolar I disorder. Bipolar Disorders, 2016, 18, 136-147.	1.9	19
529	Longitudinal predictors of subjective recovery in psychosis. British Journal of Psychiatry, 2016, 209, 48-53.	2.8	43
530	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. Revista De Psiquiatria Y Salud Mental (English Edition), 2016, 9, 219-227.	0.3	6
531	How Hyperprolactinemia Affects Sexual Function in Patients Under Antipsychotic Treatment. Journal of Clinical Psychopharmacology, 2016, 36, 422-428.	1.4	24
532	The brief negative symptom scale: validation of the German translation and convergent validity with self-rated anhedonia and observer-rated apathy. BMC Psychiatry, 2016, 16, 415.	2.6	40
533	Prediction of functional remission in first-episode psychosis: 12-month follow-up of the randomized-controlled trial on extended early intervention in Hong Kong. Schizophrenia Research, 2016, 173, 79-83.	2.0	29
534	BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.3	12
535	Are persistent delusions in schizophrenia associated with aberrant salience?. Schizophrenia Research: Cognition, 2016, 4, 32-38.	1.3	14
536	Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. Psychiatry Research, 2016, 239, 301-307.	3.3	46
537	The "Insight Paradox" in Schizophrenia: Magnitude, Moderators and Mediators of the Association Between Insight and Depression. Schizophrenia Bulletin, 2016, 42, 1225-1233.	4.3	61

539	Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study. Schizophrenia Bulletin, 2016, 42, 1253-1261.	4.3	110
540	Low vitamin D is associated with negative and depressive symptoms in psychotic disorders. Schizophrenia Research, 2016, 178, 44-49.	2.0	29
541	Comparison of psychopathology of schizophrenia ill patients with hyponatremia or normonatremia on hospital admission. Postepy Psychiatrii I Neurologii, 2016, 25, 179-189.	0.2	0
542	Biomarcadores sanguíneos diferenciales de las dimensiones psicopatológicas de la esquizofrenia. Revista De Psiquiatría Y Salud Mental, 2016, 9, 219-227.	1.8	21
543	Schizophrenia, smoking status, and performance on the matrices Cognitive Consensus Battery. Psychiatry Research, 2016, 246, 1-8.	3.3	20
544	The efficacy of cerebellar vermal deep high frequency (theta range) repetitive transcranial magnetic stimulation (rTMS) in schizophrenia: A randomized rater blind-sham controlled study. Psychiatry Research, 2016, 243, 413-420.	3.3	63
545	The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia. Psychiatric Services, 2016, 67, 1300-1306.	2.0	22
546	The intensity and correlates of the feelings of loneliness in people with psychosis. Comprehensive Psychiatry, 2016, 70, 190-199.	3.1	60
547	Coping strategies in schizoaffective disorder and schizophrenia: Differences and similarities. Psychiatry Research, 2016, 244, 317-323.	3.3	5
548	White matter correlates of episodic memory encoding and retrieval in schizophrenia. Psychiatry Research - Neuroimaging, 2016, 254, 188-198.	1.8	11
549	Moderating effects of positive symptoms of psychosis in suicidal ideation among adults diagnosed with schizophrenia. Schizophrenia Research, 2016, 176, 364-370.	2.0	22
550	Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder. Psychological Medicine, 2016, 46, 3127-3136.	4.5	37
551	Age-related cortical thickness trajectories in first episode psychosis patients presenting with early persistent negative symptoms. NPJ Schizophrenia, 2016, 2, 16029.	3.6	25
552	Validity and Reliability of the Arabic Version of the Positive and Negative Syndrome Scale. Psychopathology, 2016, 49, 181-187.	1.5	16
553	Manualized Group Cognitive-Behavioral Therapy for Social Anxiety in At-Risk Mental State and First Episode Psychosis: A Pilot Study of Feasibility and Outcomes. International Journal of Group Psychotherapy, 2016, 66, 225-245.	0.6	9
554	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Focus (American J ETQq0 0 0 qgBT /Overclock 10		
555	Ventral Striatal Dysfunction and Symptom Expression in Individuals With Schizotypal Personality Traits and Early Psychosis. Schizophrenia Bulletin, 2018, 44, sbw142.	4.3	28

#	ARTICLE	IF	CITATIONS
556	Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders. Journal of Clinical Psychopharmacology, 2016, 36, 597-607.	1.4	13
557	TechCare: mobile assessment and therapy for psychosis – an intervention for clients in the Early Intervention Service: A feasibility study protocol. SAGE Open Medicine, 2016, 4, 205031211666961.	1.8	16
558	Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. BMC Psychiatry, 2016, 16, 280.	2.6	16
559	Transcranial Direct Current Stimulation as Monotherapy for the Treatment of Auditory Hallucinations During Pregnancy. Journal of Clinical Psychopharmacology, 2016, 36, 534-535.	1.4	7
560	Antiglucocorticoid and related treatments for psychosis. The Cochrane Library, 2016, 2016, CD006995.	2.8	13
561	The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry, 2016, 16, 60.	2.6	54
562	Patient satisfaction after acute admission for psychosis. Nordic Journal of Psychiatry, 2016, 70, 321-328.	1.3	23
563	Characterizing the affective responses to an acute bout of moderate-intensity exercise among outpatients with schizophrenia. Psychiatry Research, 2016, 237, 264-270.	3.3	2
564	Early Intervention for Psychosis in Canada. Canadian Journal of Psychiatry, 2016, 61, 186-194.	1.9	50
565	Investigating the feasibility and acceptability of a cognitive behavioural suicide prevention therapy for people in acute psychiatric wards (the –INSITE–™ trial): study protocol for a randomised controlled trial. Trials, 2016, 17, 79.	1.6	22
566	Premorbid, clinical and cognitive correlates of primary negative symptoms in first-episode psychosis. Psychiatry Research, 2016, 242, 144-149.	3.3	24
567	Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC. Quality of Life Research, 2016, 25, 925-934.	3.1	12
568	The Phenomenology and Generation of Positive Mental Imagery in Early Psychosis. Clinical Psychology and Psychotherapy, 2016, 23, 523-532.	2.7	10
569	What Distinguishes Suicide Attempters From Suicide Ideators? A Meta-Analysis of Potential Factors. Clinical Psychology: Science and Practice, 2016, 23, 5-20.	0.9	242
570	Depressive symptoms in first-episode psychosis: a 10-year follow-up study. Microbial Biotechnology, 2016, 10, 227-233.	1.7	35
571	A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. Schizophrenia Research, 2016, 171, 27-34.	2.0	61
572	Free thyroxine levels are associated with cognitive changes in individuals with a first episode of psychosis: A prospective 1-year follow-up study. Schizophrenia Research, 2016, 171, 182-186.	2.0	18
573	Functional brain substrate of quality of life in patients with schizophrenia: A brain SPECT multidimensional analysis. Psychiatry Research - Neuroimaging, 2016, 249, 67-75.	1.8	5

#	ARTICLE	IF	CITATIONS
574	A cluster-analytical approach toward real-world outcome in outpatients with stable schizophrenia. <i>European Psychiatry</i> , 2016, 32, 48-54.	0.2	29
575	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2016, 170, 168-176.	2.0	34
576	The Role of Insight in Moderating the Association Between Depressive Symptoms in People With Schizophrenia and Stigma Among Their Nearest Relatives: A Pilot Study. <i>Schizophrenia Bulletin</i> , 2016, 42, 600-607.	4.3	10
577	Childhood adversity and social functioning in psychosis: Exploring clinical and cognitive mediators. <i>Psychiatry Research</i> , 2016, 238, 25-32.	3.3	48
578	Motivation and Pleasure Scale-Self-Report (MAP-SR): Validation of the German version of a self-report measure for screening negative symptoms in schizophrenia. <i>Comprehensive Psychiatry</i> , 2016, 65, 110-115.	3.1	27
579	Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 267-271.	1.3	49
580	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). <i>Psychosis</i> , 2016, 8, 143-155.	0.8	2
581	The Function Biomedical Informatics Research Network Data Repository. <i>NeuroImage</i> , 2016, 124, 1074-1079.	4.2	114
582	Neurocognitive impairment in the deficit subtype of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 397-407.	3.2	21
583	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 4-20.	1.8	18
584	Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis. <i>Psychiatry Research</i> , 2017, 249, 39-45.	3.3	13
585	Factor analysis of Y-BOCS checklist and severity scale among patients with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2017, 26, 141-145.	2.0	4
586	Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 113-119.	4.8	3
587	Obsessive Compulsive Symptoms/disorder in patients with schizophrenia: Prevalence, relationship with other symptom dimensions and impact on functioning. <i>Psychiatry Research</i> , 2017, 250, 277-284.	3.3	28
588	Predictors of current functioning and functional decline in schizophrenia. <i>Schizophrenia Research</i> , 2017, 188, 158-164.	2.0	37
589	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	10.4	156
590	Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. <i>Schizophrenia Research</i> , 2017, 189, 126-133.	2.0	32
591	The psychometric validity of the Center for Epidemiological Studies "Depression Scale (CES-D) in first episode schizophrenia spectrum. <i>Psychiatry Research</i> , 2017, 252, 16-22.	3.3	18

#	ARTICLE	IF	CITATIONS
592	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. International Journal of Psychiatry in Clinical Practice, 2017, 21, 82-90.	2.4	61
593	Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes. Psychological Medicine, 2017, 47, 2461-2471.	4.5	29
594	Relationship of depression with cognitive insight and socio-occupational outcome in patients with schizophrenia. International Journal of Social Psychiatry, 2017, 63, 181-194.	3.1	11
595	Investigating consummatory and anticipatory pleasure across motivation deficits in schizophrenia and healthy controls. Psychiatry Research, 2017, 254, 112-117.	3.3	27
596	Enhancing tolerability of a measure of social perception in schizophrenia: comparison of short and long Norwegian versions of the Relationships Across Domains test. Cognitive Neuropsychiatry, 2017, 22, 254-262.	1.3	7
597	Early clinical recovery in first-episode psychosis: Symptomatic remission and its correlates at 1-year follow-up. Psychiatry Research, 2017, 254, 118-125.	3.3	27
598	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). Schizophrenia Research, 2017, 183, 143-150.	2.0	29
599	Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology, 2017, 234, 2113-2125.	3.1	36
600	Comparison of depression symptoms between primary depression and secondary-to-schizophrenia depression. International Journal of Psychiatry in Clinical Practice, 2017, 21, 314-317.	2.4	30
601	A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. Journal of Clinical Psychopharmacology, 2017, 37, 394-400.	1.4	28
602	Prediction of motivational impairment: 12-month follow-up of the randomized-controlled trial on extended early intervention for first-episode psychosis. European Psychiatry, 2017, 41, 37-41.	0.2	11
603	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. Revista De Psiquiatria Y Salud Mental (English Edition), 2017, 10, 4-20.	0.3	7
604	A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment. Psychopharmacology, 2017, 234, 1045-1058.	3.1	5
605	Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis. Schizophrenia Research, 2017, 184, 116-121.	2.0	29
606	Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program. Psychiatry Research, 2017, 247, 113-119.	3.3	54
607	Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychological Medicine, 2017, 47, 363-375.	4.5	23
608	Linking persistent negative symptoms to amygdala-hippocampus structure in first-episode psychosis. Translational Psychiatry, 2017, 7, e1195-e1195.	4.8	36
609	Childhood trauma, depression, and sleep quality and their association with psychotic symptoms and suicidality in schizophrenia. Psychiatry Research, 2017, 258, 557-564.	3.3	23

#	ARTICLE	IF	CITATIONS
610	Reviewing the Effectiveness of Music Interventions in Treating Depression. <i>Frontiers in Psychology</i> , 2017, 8, 1109.	2.1	102
611	Safety and Efficacy of Theta-Burst Stimulation in the Treatment of Psychiatric Disorders. <i>Journal of Nervous and Mental Disease</i> , 2017, 205, 823-839.	1.0	29
612	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. <i>Journal of Psychiatric Research</i> , 2017, 94, 62-69.	3.1	14
613	Wendan decoction (Traditional Chinese medicine) for schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD012217.	2.8	12
614	Smoking status and its relationship to demographic and clinical characteristics in first episode psychosis. <i>Journal of Psychiatric Research</i> , 2017, 85, 83-90.	3.1	19
615	Employment outcome and predictors of competitive employment at 2-year follow-up of a vocational rehabilitation programme for individuals with schizophrenia in a high-income welfare society. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 180-187.	1.3	31
616	Symptoms of Depression, Positive Symptoms of Psychosis, and Suicidal Ideation Among Adults Diagnosed With Schizophrenia Within the Clinical Antipsychotic Trials of Intervention Effectiveness. <i>Archives of Suicide Research</i> , 2017, 21, 633-645.	2.3	19
617	Evidence for a differential contribution of early perceptual and late cognitive processes during encoding to episodic memory impairment in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 369-381.	2.6	10
618	Longitudinal trajectory of clinical insight and covariation with cortical thickness in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2017, 86, 46-54.	3.1	16
619	Leukocyte telomere length: Effects of schizophrenia, age, and gender. <i>Journal of Psychiatric Research</i> , 2017, 85, 42-48.	3.1	35
620	Bipolar disorder risk gene FOXO6 modulates negative symptoms in schizophrenia: a neuroimaging genetics study. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 172-180.	2.4	4
621	Parameter-Based Evaluation of Attentional Impairments in Schizophrenia and Their Modulation by Prefrontal Transcranial Direct Current Stimulation. <i>Frontiers in Psychiatry</i> , 2017, 8, 259.	2.6	9
622	The Functional Significance of Affect Recognition, Neurocognition, and Clinical Symptoms in Schizophrenia. <i>PLoS ONE</i> , 2017, 12, e0170114.	2.5	7
623	Pilot randomised controlled trial of culturally adapted cognitive behavior therapy for psychosis (CaCBTp) in Pakistan. <i>BMC Health Services Research</i> , 2017, 17, 808.	2.2	14
624	Motivational impairment predicts functional remission in first-episode psychosis: 3-Year follow-up of the randomized controlled trial on extended early intervention. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1194-1201.	2.3	16
626	Effects of a lifestyle intervention on psychosocial well-being of severe mentally ill residential patients: ELIPS, a cluster randomized controlled pragmatic trial. <i>Schizophrenia Research</i> , 2018, 199, 407-413.	2.0	25
627	A review of physiological and behavioral monitoring with digital sensors for neuropsychiatric illnesses. <i>Physiological Measurement</i> , 2018, 39, 05TR01.	2.1	86
628	Latent <i>Toxoplasma gondii</i> infection is associated with decreased serum triglyceride to high-density lipoprotein cholesterol ratio in male patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2018, 82, 115-120.	3.1	6

#	ARTICLE	IF	CITATIONS
629	Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 187-205.	4.5	59
630	Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the <scp>PULSAR</scp> study). <i>Human Psychopharmacology</i> , 2018, 33, e2652.	1.5	11
631	Determinants of Quality of Life in Spanish outpatients with schizophrenia spectrum disorders. <i>European Journal of Psychiatry</i> , 2018, 32, 113-121.	1.3	10
632	Co-morbid depressive disorder is associated with better neurocognitive performance in first episode schizophrenia spectrum. <i>Journal of Affective Disorders</i> , 2018, 229, 498-505.	4.1	10
633	Loneliness in psychosis: a systematic review. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2018, 53, 221-238.	3.1	149
634	Investigating the roles of loneliness and clinician- and self-rated depressive symptoms in predicting the subjective quality of life among people with psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2018, 53, 183-193.	3.1	10
635	Attenuated Notch signaling in schizophrenia and bipolar disorder. <i>Scientific Reports</i> , 2018, 8, 5349.	3.3	37
636	Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1070-1080.	4.3	160
637	The relationship between negative symptoms and depression in schizophrenia: a systematic review. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 380-390.	4.5	133
638	Dimensions of insight in schizophrenia: Exploratory factor analysis of items from multiple self- and interviewer-rated measures of insight. <i>Schizophrenia Research</i> , 2018, 199, 319-325.	2.0	17
639	Immigrants' outcome after a first-episode psychosis. <i>Microbial Biotechnology</i> , 2018, 12, 193-201.	1.7	6
640	Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (<scp>ACCESS) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	6
641	Positive mental health in schizophrenia and healthy comparison groups: relationships with overall health and biomarkers. <i>Aging and Mental Health</i> , 2018, 22, 354-362.	2.8	20
642	The Prevalence of Sleep Disturbance and Its Socio-demographic and Clinical Correlates in First-episode Individuals With Schizophrenia in Rural China. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 31-38.	1.9	17
643	Inverse association between negative symptoms and body mass index in chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 69-74.	2.0	25
644	Modernizing quality of life assessment: development of a multidimensional computerized adaptive questionnaire for patients with schizophrenia. <i>Quality of Life Research</i> , 2018, 27, 1041-1054.	3.1	10
645	The effects of glycine on auditory mismatch negativity in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 61-69.	2.0	46
646	A longitudinal study of cognitive insight and cortical thickness in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 193, 251-260.	2.0	15

#	ARTICLE	IF	CITATIONS
647	Clinical utility of the Calgary Depression Scale for Schizophrenia in individuals at ultra-high risk of psychosis. <i>Schizophrenia Research</i> , 2018, 193, 423-427.	2.0	18
648	Factor analysis of symptom dimensions (psychotic, affective and obsessive compulsive symptoms) in schizophrenia. <i>Asian Journal of Psychiatry</i> , 2018, 38, 72-77.	2.0	9
649	Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture. <i>Schizophrenia Research</i> , 2018, 195, 122-129.	2.0	3
650	Combining actigraphy, ecological momentary assessment and neuroimaging to study apathy in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 195, 176-182.	2.0	58
651	A state-independent network of depressive, negative and positive symptoms in male patients with schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2018, 193, 232-239.	2.0	58
652	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , 2018, 175, 169-179.	7.2	46
653	Pregabalin for anxiety in patients with schizophrenia – A randomized, double-blind placebo-controlled study. <i>Schizophrenia Research</i> , 2018, 195, 260-266.	2.0	8
654	Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis. <i>Schizophrenia Research</i> , 2018, 195, 481-487.	2.0	6
655	Prediction of self-stigma in early psychosis: 3-Year follow-up of the randomized-controlled trial on extended early intervention. <i>Schizophrenia Research</i> , 2018, 195, 463-468.	2.0	26
656	Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 585-595.	2.3	11
657	Neurological soft signs significantly differentiate schizophrenia patients from healthy controls. <i>Acta Neuropsychiatrica</i> , 2018, 30, 97-105.	2.1	17
658	Gender Differences in Social Cognition: A Cross-Sectional Pilot Study of Recently Diagnosed Patients with Schizophrenia and Healthy Subjects. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 538-546.	1.9	40
659	Investigating the predictors of happiness, life satisfaction and success in schizophrenia. <i>Comprehensive Psychiatry</i> , 2018, 81, 42-47.	3.1	23
660	Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder. <i>Nutrients</i> , 2018, 10, 1707.	4.1	31
661	Microstructural Findings in White Matter Associated with Cannabis and Alcohol Use in Early-Phase Psychosis: A Diffusion Tensor Imaging and Relaxometry Study. <i>Brain Connectivity</i> , 2018, 8, 567-576.	1.7	3
662	Comparing cognitive clusters across first- and multiple-episode of psychosis. <i>Psychiatry Research</i> , 2018, 269, 707-718.	3.3	19
663	Clinical correlates of hypothalamic-pituitary-adrenal axis measures in individuals at risk for psychosis and with first-episode psychosis. <i>Psychiatry Research</i> , 2018, 265, 284-291.	3.3	8
664	Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia. <i>Schizophrenia Research and Treatment</i> , 2018, 2018, 1-8.	1.5	6

#	ARTICLE	IF	CITATIONS
665	The Brief Negative Symptom Scale: Validation in a multicenter Brazilian study. <i>Comprehensive Psychiatry</i> , 2018, 85, 42-47.	3.1	12
666	Adjunct transcranial direct current stimulation improves cognitive function in patients with schizophrenia: A double-blind 12-week study. <i>Schizophrenia Research</i> , 2018, 197, 378-385.	2.0	45
667	Objective investigation of activity preference in schizophrenia: A pilot study. <i>Psychiatry Research</i> , 2018, 267, 551-559.	3.3	1
668	Frontal hypoactivation and alterations in the reward-system during humor processing in patients with schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2018, 202, 149-157.	2.0	11
669	Improving working memory in schizophrenia: Effects of 1â€mA and 2â€mA transcranial direct current stimulation to the left DLPFC. <i>Schizophrenia Research</i> , 2018, 202, 203-209.	2.0	31
670	Investigating the association of ventral and dorsal striatal dysfunction during reward anticipation with negative symptoms in patients with schizophrenia and healthy individuals. <i>PLoS ONE</i> , 2018, 13, e0198215.	2.5	34
671	Toward a transdiagnostic tool to evaluate depressive symptoms across mental disorders: Validation of the Calgary depression rating scale in patients with major depressive disorder. <i>Psychiatry Research</i> , 2018, 268, 68-71.	3.3	6
672	Stability in basic self-disturbances and diagnosis in a first treated psychosis: A seven year follow-up study. <i>Schizophrenia Research</i> , 2018, 202, 274-280.	2.0	16
673	Development of the Demotivating Beliefs Inventory and Test of the Cognitive Triad of Amotivation. <i>Cognitive Therapy and Research</i> , 2018, 42, 867-877.	1.9	10
674	Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. <i>Lancet Psychiatry</i> , 2018, 5, 633-643.	7.4	71
675	Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers. <i>BMJ Open</i> , 2018, 8, e021346.	1.9	11
676	Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). <i>Psychiatry Research</i> , 2018, 268, 447-453.	3.3	15
677	Structural equation modeling approach between salience network dysfunction, depressed mood, and subjective quality of life in schizophrenia: an ICA resting-state fMRI study. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1585-1597.	2.2	11
678	In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. <i>Neuroscience Letters</i> , 2018, 684, 152-155.	2.1	11
679	Consequences of persistent depression and apathy in first-episode psychosis â€” A one-year follow-up study. <i>Comprehensive Psychiatry</i> , 2018, 86, 60-66.	3.1	9
680	Comparison of neurocognitive domains in patients with schizophrenia with and without co-morbid obsessive compulsive disorder. <i>Schizophrenia Research</i> , 2018, 201, 151-158.	2.0	13
681	Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment. <i>Journal of Psychiatric Research</i> , 2018, 103, 219-228.	3.1	6
682	Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 357-361.	1.4	4

#	ARTICLE	IF	CITATIONS
683	Rigidity in Motor Behavior and Brain Functioning in Patients With Schizophrenia and High Levels of Apathy. <i>Schizophrenia Bulletin</i> , 2019, 45, 542-551.	4.3	9
685	Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study. <i>Pharmacopsychiatry</i> , 2019, 52, 142-146.	3.3	1
686	Validation of the Danish version of the brief negative symptom scale. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 425-432.	1.3	16
687	Predictors of treatment satisfaction in antipsychotic-naïve and previously medicated patients with acute-phase psychosis. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 349-356.	1.3	3
688	Basic self-disturbances independently predict recovery in psychotic disorders: A seven year follow-up study. <i>Schizophrenia Research</i> , 2019, 212, 72-78.	2.0	12
689	Distinct Differences in Emotional Recognition According to Severity of Psychotic Symptoms in Early-Stage Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 564.	2.6	11
690	Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study. <i>British Journal of Psychiatry</i> , 2019, 215, 712-719.	2.8	25
691	The effect of second-generation antipsychotics on basal ganglia and thalamus in first-episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2019, 29, 1408-1418.	0.7	6
692	Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. <i>Psychiatry Research</i> , 2019, 282, 112492.	3.3	24
693	The effect of baseline antipsychotic status on the 12-month outcome in initially stabilized patients with schizophrenia. <i>Human Psychopharmacology</i> , 2019, 34, e2712.	1.5	2
694	12-Month stability of neurological soft signs in stabilized patients with schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 451-461.	1.3	5
695	The Persian version of the Calgary Depression Scale for Schizophrenia (CDSS-P). <i>Asian Journal of Psychiatry</i> , 2019, 45, 44-49.	2.0	3
696	An Asian study on clinical and psychological factors associated with personal recovery in people with psychosis. <i>BMC Psychiatry</i> , 2019, 19, 256.	2.6	17
697	Efficacy of low-dose D ₂ /D ₃ -partial Agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2195-2203.	2.2	5
698	The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis. <i>Psychological Medicine</i> , 2019, 49, 2486-2498.	4.5	23
699	Depressive psychopathology in first-episode schizophrenia spectrum disorders: a systematic review, meta-analysis and meta-regression. <i>Psychological Medicine</i> , 2019, 49, 2463-2474.	4.5	39
700	The latent structure of depressive symptoms across clinical high risk and chronic phases of psychotic illness. <i>Translational Psychiatry</i> , 2019, 9, 229.	4.8	9
701	Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic Imaging. <i>Nature Communications</i> , 2019, 10, 4493.	12.8	30

#	ARTICLE	IF	CITATIONS
702	Theory of mind in schizophrenia and bipolar disorder: psychometric properties of the Norwegian version of the Hinting Task. <i>Cognitive Neuropsychiatry</i> , 2019, 24, 454-469.	1.3	9
703	The nature of bradykinesia in schizophrenia treated with antipsychotics. <i>Psychiatry Research</i> , 2019, 273, 537-543.	3.3	6
704	Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia. <i>Journal of Affective Disorders</i> , 2019, 246, 745-753.	4.1	19
705	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. <i>Translational Psychiatry</i> , 2019, 9, 20.	4.8	52
706	A comparative study of childhood/adolescent and adult onset schizophrenia: does the neurocognitive and psychosocial outcome differ?. <i>Asian Journal of Psychiatry</i> , 2019, 43, 160-169.	2.0	16
707	Sex Differences in Clinical and Functional Outcomes among Patients Treated in an Early Intervention Service for Psychotic Disorders: An Observational Study. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 070674371985406.	1.9	12
708	Tobacco smoking and nicotine dependence in first episode and established psychosis. <i>Asian Journal of Psychiatry</i> , 2019, 43, 125-131.	2.0	25
709	Correlates of Future Violence in People Being Treated for Schizophrenia. <i>American Journal of Psychiatry</i> , 2019, 176, 694-701.	7.2	53
710	Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling. <i>Schizophrenia Research</i> , 2019, 208, 82-89.	2.0	16
711	In vitro cytokine synthesis in unstimulated and mitogen-stimulated peripheral blood mononuclear cells from individuals with schizophrenia. <i>Journal of Investigative Medicine</i> , 2019, 67, 1053-1060.	1.6	1
712	Longitudinal associations of family burden and patient quality of life in the context of first-episode schizophrenia in the RAISE-ETP study. <i>Psychiatry Research</i> , 2019, 276, 60-68.	3.3	10
713	The relationship between self-stigma and depression among people with schizophrenia-spectrum disorders: A longitudinal study.. <i>Psychiatry Research</i> , 2019, 275, 115-119.	3.3	28
714	Diagnostic and symptom interviews for adults. , 2019, , 355-393.		2
715	The association of clinical insight and depression with quality of life in schizophrenia. <i>Psychiatry Research</i> , 2019, 279, 350-352.	3.3	12
716	Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1917-1924.	5.4	24
717	Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1589-1596.	5.4	26
718	EEG correlates of face recognition in patients with schizophrenia spectrum disorders: A systematic review. <i>Clinical Neurophysiology</i> , 2019, 130, 986-996.	1.5	19
719	Validation of the Brief Negative Symptom Scale and its association with functioning. <i>Schizophrenia Research</i> , 2019, 208, 97-104.	2.0	42

#	ARTICLE	IF	CITATIONS
720	Comparison of schizophrenia outpatients in residential care facilities with those living with someone: Study of mental and physical health, cognitive functioning, and biomarkers of aging. <i>Psychiatry Research</i> , 2019, 275, 162-168.	3.3	13
721	Feasibility and acceptability of suicide prevention therapy on acute psychiatric wards: randomised controlled trial. <i>BJPsych Open</i> , 2019, 5, e14.	0.7	23
722	Self-Awareness of Psychopathology and Brain Volume in Patients With First Episode Psychosis. <i>Frontiers in Psychiatry</i> , 2019, 10, 839.	2.6	5
723	Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia. <i>European Neuropsychopharmacology</i> , 2019, 29, 1433-1441.	0.7	5
724	Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study. <i>Schizophrenia Research</i> , 2019, 204, 381-388.	2.0	16
725	The effects of combined oxytocin and cognitive behavioral social skills training on social cognition in schizophrenia. <i>Psychological Medicine</i> , 2019, 49, 1731-1739.	4.5	16
726	Positive and negative symptoms in schizophrenia: A longitudinal analysis using latent variable structural equation modelling. <i>Schizophrenia Research</i> , 2019, 204, 58-64.	2.0	32
727	Establishing Clinical Cutoff Values for the Beck Cognitive Insight Scale. <i>Cognitive Therapy and Research</i> , 2019, 43, 324-334.	1.9	4
728	Factor Analysis of Negative Symptom Items in the Structured Interview for Prodromal Syndromes. <i>Schizophrenia Bulletin</i> , 2019, 45, 1042-1050.	4.3	24
729	Objective and subjective cognitive functioning in relation to psychopathology among women with early psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 1227-1235.	1.7	4
730	The expression of toll-like receptors in peripheral blood mononuclear cells is altered in schizophrenia. <i>Psychiatry Research</i> , 2019, 272, 540-550.	3.3	19
731	Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. <i>Acta Neuropsychiatrica</i> , 2019, 31, 36-45.	2.1	15
732	Differences in Facial Emotional Recognition Between Patients With the First-Episode Psychosis, Multi-episode Schizophrenia, and Healthy Controls. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 165-173.	1.8	17
733	Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environment. <i>Schizophrenia Research</i> , 2019, 206, 400-406.	2.0	9
734	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 598-605.	5.4	207
735	The role of illness engulfment in the association between insight and depressive symptomatology in schizophrenia. <i>Journal of Psychiatric Research</i> , 2019, 111, 1-7.	3.1	17
736	Assessing negative symptoms in schizophrenia: Validity of the clinical assessment interview for negative symptoms in Singapore. <i>Schizophrenia Research</i> , 2019, 206, 177-182.	2.0	14
737	The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B12, B6, and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis. <i>Biological Psychiatry</i> , 2019, 86, 35-44.	1.3	23

#	ARTICLE	IF	CITATIONS
738	The Global Functioning: Social and Role Scalesâ€”Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2019, 45, 763-772.	4.3	55
740	Cognitive capacity similarly predicts insight into symptoms in first- and multiple-episode psychosis. Schizophrenia Research, 2019, 206, 236-243.	2.0	6
741	Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis. JAMA Psychiatry, 2019, 76, 61.	11.0	33
742	Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectrums, 2019, 24, 239-248.	1.2	19
743	Suicidal Ideation in Firstâ€”Episode Psychosis (FEP): Examination of Symptoms of Depression and Psychosis Among Individuals in an Early Phase of Treatment. Suicide and Life-Threatening Behavior, 2019, 49, 423-431.	1.9	41
744	Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1â€”year after their first in-patient treatment. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 459-468.	3.2	19
745	Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 795-802.	3.2	17
746	Is loneliness a feasible treatment target in psychosis?. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 901-906.	3.1	17
747	Clinical and psychosocial factors associated with depression in patients with psychosis according to stage of illness. Microbial Biotechnology, 2020, 14, 44-52.	1.7	13
748	Shared and dissociable features of apathy and reward system dysfunction in bipolar I disorder and schizophrenia. Psychological Medicine, 2020, 50, 936-947.	4.5	19
749	Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. Psychological Medicine, 2020, 50, 595-606.	4.5	23
750	A pilot digital intervention targeting loneliness in young people with psychosis. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 877-889.	3.1	61
751	The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling. Psychological Medicine, 2020, 50, 566-574.	4.5	12
752	Quality of parental bonding is associated with symptom severity and functioning among individuals at ultra-high risk for psychosis. Schizophrenia Research, 2020, 215, 204-210.	2.0	9
753	Association between antiâ€”thyroid antibodies and negative symptoms in early psychosis. Microbial Biotechnology, 2020, 14, 470-475.	1.7	19
754	Deep brain stimulation in treatment resistant schizophrenia: A pilot randomized cross-over clinical trial. EBioMedicine, 2020, 51, 102568.	6.1	50
755	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia. JAMA Psychiatry, 2020, 77, 349.	11.0	226
756	Assessing analytic and intuitive reasoning using the cognitive reflection test in young patients with schizophrenia. Psychiatry Research, 2020, 284, 112683.	3.3	5

#	ARTICLE	IF	CITATIONS
757	Cognitive behavior therapy in early psychosis with a focus on depression and low self-esteem: A randomized controlled trial. <i>Comprehensive Psychiatry</i> , 2020, 97, 152157.	3.1	18
758	Independent effect of childhood trauma and recent stress as predictors for current suicidal ideation in schizophrenia. <i>General Hospital Psychiatry</i> , 2020, 64, 115-116.	2.4	4
759	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100161.	1.3	2
760	Delay discounting abnormalities are seen in first-episode schizophrenia but not in bipolar disorder. <i>Schizophrenia Research</i> , 2020, 216, 200-206.	2.0	10
761	Psychological factors intervening between childhood trauma and suicidality in first-episode psychosis. <i>Psychiatry Research</i> , 2020, 293, 113465.	3.3	4
762	The psychometric properties of the Self-Evaluation of Negative Symptoms Scale (SNS) in treatment-resistant schizophrenia (TRS). <i>Schizophrenia Research</i> , 2020, 224, 159-166.	2.0	7
763	Psychiatric, cognitive functioning and socio-cultural views of menstrual psychosis in Oman: an idiographic approach. <i>BMC Women's Health</i> , 2020, 20, 215.	2.0	4
764	An 18-month longitudinal study of suicidality in patients diagnosed with schizophrenia. <i>Schizophrenia Research</i> , 2020, 224, 102-107.	2.0	3
765	Depression in schizophrenia: Prevalence and its impact on quality of life, disability, and functioning. <i>Asian Journal of Psychiatry</i> , 2020, 54, 102425.	2.0	12
766	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. <i>European Psychiatry</i> , 2020, 63, 1-21.	0.2	30
767	Disentangling the relationship between cholesterol, aggression, and impulsivity in severe mental disorders. <i>Brain and Behavior</i> , 2020, 10, e01751.	2.2	5
768	Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 223, 279-288.	2.0	5
769	Effects of Smoking Status on Remission and Metabolic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine. <i>Pharmacopsychiatry</i> , 2020, 53, 273-283.	3.3	2
770	Associations between childhood adversity, cognitive schemas and attenuated psychotic symptoms. <i>Microbial Biotechnology</i> , 2021, 15, 818-827.	1.7	10
771	Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 444-450.	1.4	5
772	Effects of Exercise on Resilience, Insight and Functionality in Patients with Chronic Schizophrenia in a Psychiatric Nursing Home Setting: A Randomized Controlled Trial. <i>Issues in Mental Health Nursing</i> , 2021, 42, 690-698.	1.2	10
773	The Psychology of Food Cravings in Patients With First-Episode Psychosis. <i>Frontiers in Psychiatry</i> , 2020, 11, 587486.	2.6	5
774	Is self-compassion linked to treatment adherence in schizophrenia?. <i>Schizophrenia Research</i> , 2020, 222, 493-495.	2.0	3

#	ARTICLE	IF	CITATIONS
775	Effects of antipsychotics on rumination in patients with first-episode psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 103, 109983.	4.8	2
776	â€œI just don't look forward to anythingâ€: How anticipatory pleasure and negative beliefs contribute to goal-directed activity in patients with negative symptoms of psychosis. Schizophrenia Research, 2020, 222, 429-436.	2.0	15
777	A psychological intervention for suicide applied to non-affective psychosis: the CARMS (Cognitive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 20, 306.	2.6	14
778	Impact of the group intervention "Accept VoicesÂ©" for the management of auditory hallucinations. Psychiatry Research, 2020, 291, 113159.	3.3	7
779	Validation and extension of the Motivation and Pleasure Scale-Self Report (MAP-SR) across the schizophrenia spectrum in the Chinese context. Asian Journal of Psychiatry, 2020, 49, 101971.	2.0	12
780	Using the CHIME Personal Recovery Framework to Evaluate the Validity of the MHRM-10 in Individuals with Psychosis. Psychiatric Quarterly, 2020, 91, 793-805.	2.1	5
781	Assessment of obsessive-compulsive disorder comorbidity and obsessive-compulsive symptom dimensions in patients with schizophrenia. Journal of King Abdulaziz University, Islamic Economics, 2020, 41, 275-282.	1.1	5
782	Free Thyroxine Concentrations Moderate the Response to a Cognitive Remediation Therapy in People With Early Psychosis: A Pilot Randomized Clinical Trial. Frontiers in Psychiatry, 2020, 11, 636.	2.6	1
783	A Retrospective Study of the Clinical Characteristics Associated with Alcohol and Cannabis use in Early Phase Psychosis. Canadian Journal of Psychiatry, 2020, 65, 426-435.	1.9	12
784	Associations between schizophrenia polygenic risk and apathy in schizophrenia spectrum disorders and healthy controls. Acta Psychiatrica Scandinavica, 2020, 141, 452-464.	4.5	2
785	The brief negative symptom scale in translation: A review of psychometric properties and beyond. European Neuropsychopharmacology, 2020, 33, 36-44.	0.7	14
786	Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial. Trials, 2020, 21, 14.	1.6	10
787	Mediation and moderation analyses: exploring the complex pathways between hope and quality of life among patients with schizophrenia. BMC Psychiatry, 2020, 20, 22.	2.6	25
788	Understanding sex differences in cognitive insight across first-and-multiple episode psychosis. Schizophrenia Research, 2020, 218, 276-282.	2.0	6
789	Leukocyte and brain DDR1 hypermethylation is altered in psychosis and is correlated with stress and inflammatory markers. Epigenomics, 2020, 12, 251-265.	2.1	8
790	Sex Differences in Verbal Memory Predict Functioning Through Negative Symptoms in Early Psychosis. Schizophrenia Bulletin, 2020, 46, 1587-1595.	4.3	20
791	A conversational recommender system for diagnosis using fuzzy rules. Expert Systems With Applications, 2020, 154, 113449.	7.6	23
792	Longitudinal predictors of stigma in firstâ€episode psychosis: Mediating effects of depression. Microbial Biotechnology, 2021, 15, 263-270.	1.7	6

#	ARTICLE	IF	CITATIONS
793	Depression: An actionable outcome for those at clinical high-risk. Schizophrenia Research, 2021, 227, 38-43.	2.0	7
794	Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain, Behavior, and Immunity, 2021, 91, 498-504.	4.1	28
795	Suicidality Over the First 5 Years of Psychosis: Does Extending Early Intervention Have Benefits?. Canadian Journal of Psychiatry, 2021, 66, 468-476.	1.9	6
796	Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study). Human Psychopharmacology, 2021, 36, e2770.	1.5	1
797	Self-concept and Engagement in LiFe (SELF): A waitlist-controlled pilot study of a novel psychological intervention to target illness engulfment in enduring schizophrenia and related psychoses. Schizophrenia Research, 2021, 228, 567-574.	2.0	4
798	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biological Psychiatry, 2021, 90, 9-15.	1.3	14
799	The frontal pole and cognitive insight in schizophrenia. Psychiatry Research - Neuroimaging, 2021, 308, 111236.	1.8	10
800	Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2021, 47, 298-308.	4.3	45
801	Stability of Verbal Fluency in Outpatients with Schizophrenia. Psychiatry Research, 2021, 295, 113528.	3.3	5
802	A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. Advances in Pharmacology, 2021, 90, 253-276.	2.0	16
803	Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia. Nordic Journal of Psychiatry, 2021, 75, 135-144.	1.3	14
804	The Long-Term Relationship Between Psychological Resilience, Psychosis, Distress, and Suicidal Thoughts and Behaviors. Schizophrenia Bulletin Open, 2021, 2, .	1.7	7
805	Reducing negative symptoms in schizophrenia: Feasibility and acceptability of a combined cognitive-behavioral social skills training and compensatory cognitive training intervention. Psychiatry Research, 2021, 295, 113620.	3.3	10
806	A Comprehensive Survey of Different Phases for Involuntary System for Face Emotion Recognition. Communications in Computer and Information Science, 2021, , 169-182.	0.5	2
807	The Complement C4 Genetic Diversity in First Episode Psychosis of the OPTiMiSE Cohort. Schizophrenia Bulletin Open, 2021, 2, .	1.7	5
808	Use of Parametric Methods and Questionnaires for the Study of Depressive and Anxiety Disorders in Schizophrenia. Doctor Ru, 2021, 20, 55-61.	0.3	2
809	Inflexibility in Reasoning: Comparisons of Cognitive Flexibility, Explanatory Flexibility, and Belief Flexibility Between Schizophrenia and Major Depressive Disorder. Frontiers in Psychiatry, 2020, 11, 609569.	2.6	11
810	Illicit substances detected through high-resolution MS analysis in urine samples are associated with greater symptom burden in patients with psychosis. Emerging Trends in Drugs, Addictions, and Health, 2021, 1, 100024.	1.1	0

#	ARTICLE	IF	CITATIONS
811	Early Detection of Ultra High Risk for Psychosis in a Norwegian Catchment Area: The Two Year Follow-Up of the Prevention of Psychosis Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 573905.	2.6	12
812	Disentangling the relationships between interpersonal competence, social network, social support and the experience of being stigmatized among people with psychotic disorders: A path modeling approach. <i>Schizophrenia Research</i> , 2021, 228, 305-310.	2.0	4
813	The psychometric validity of the Montgomery-Åsberg Depression Rating Scale (MADRS) in recent onset schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2021, 228, 373-381.	2.0	5
814	Exploring the Psychometric Properties and the Factor Structure of the Calgary Depression Scale for Schizophrenia Across the Schizotypy Continuum. <i>Assessment</i> , 2022, 29, 686-699.	3.1	4
815	Suicidal ideation in first-episode psychosis: Considerations for depression, positive symptoms, clinical insight, and cognition. <i>Schizophrenia Research</i> , 2021, 228, 298-304.	2.0	14
816	Clinical risk factors, phenomenology and the impact of clozapine induced obsessive compulsive symptoms. <i>Psychiatry Research</i> , 2021, 296, 113665.	3.3	5
817	Longitudinal symptom network structure in first-episode psychosis: a possible marker for remission. <i>Psychological Medicine</i> , 2022, 52, 3193-3201.	4.5	6
818	Expression of Dopamine D1 and Serotonin 5-HT1A-3A Receptors in Blood Mononuclear Cells in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 645081.	2.6	10
819	Recognition and management of depression in early psychosis. <i>BJPsych Bulletin</i> , 2022, 46, 83-89.	1.1	4
820	Adjuvant High-Definition Transcranial Direct Current Stimulation for Negative Symptoms in Schizophrenia. <i>Journal of ECT</i> , 2021, 37, 195-201.	0.6	7
821	Investigating potential associations between neurocognition/social cognition and oxidative stress in schizophrenia. <i>Psychiatry Research</i> , 2021, 298, 113832.	3.3	13
822	The impact of family environment on self-esteem and symptoms in early psychosis. <i>PLoS ONE</i> , 2021, 16, e0249721.	2.5	4
823	Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 236-243.	1.4	13
824	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. <i>Schizophrenia Bulletin Open</i> , 0, .	1.7	2
825	The role of depression in the prediction of a relapse-remission in first-episode psychosis: An analysis of the OPTiMiSE study. <i>Schizophrenia Research</i> , 2021, 231, 100-107.	2.0	4
826	Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. <i>Scientific Reports</i> , 2021, 11, 9992.	3.3	22
827	Impact of childhood trauma on positive and negative symptom remission in first episode psychosis. <i>Schizophrenia Research</i> , 2021, 231, 82-89.	2.0	15
828	Mediating effect of genome-wide DNA methylation on suicidal ideation induced by perceived stress. <i>Psychiatric Genetics</i> , 2021, Publish Ahead of Print, 168-176.	1.1	2

#	ARTICLE	IF	CITATIONS
829	Neurocognitive functions in persistent negative symptoms following a first episode of psychosis. <i>European Neuropsychopharmacology</i> , 2021, 47, 86-97.	0.7	12
830	A blinded validation of the Swedish version of the Clinical Assessment Interview for Negative Symptoms (CAINS). <i>Nordic Journal of Psychiatry</i> , 2022, 76, 44-51.	1.3	4
831	Psychosis and Hopelessness Mediate the Relationship Between Reduced Sleep and Suicidal Ideation in Schizophrenia Spectrum Disorders. <i>Archives of Suicide Research</i> , 2022, 26, 1862-1879.	2.3	3
832	The relationship between self-criticism and suicide probability. <i>Clinical Psychology and Psychotherapy</i> , 2021, 28, 1445-1456.	2.7	12
833	Effects of Cognitive Remediation on Cognition, Metacognition, and Social Cognition in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 649737.	2.6	7
834	Dynamic Interplay Between Insight and Persistent Negative Symptoms in First Episode of Psychosis: A Longitudinal Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 211-219.	4.3	9
835	Clinical and psychological correlates of insight dimensions in patients with early psychosis. <i>Microbial Biotechnology</i> , 2021, , .	1.7	2
836	Differential Item Functioning in the WHODAS 2.0 Scale in Schizophrenia: An Application of the Rasch Trees Method Based on Demographic and Clinical Covariates. <i>Assessment</i> , 2021, , 107319112110367.	3.1	0
837	Group and sex differences in social cognition in bipolar disorder, schizophrenia/schizoaffective disorder and healthy people. <i>Comprehensive Psychiatry</i> , 2021, 109, 152258.	3.1	16
838	Carepath for overcoming psychosis early (COPE): first 5 years of clinical operation and prospective research in the Cavanagh Monaghan early intervention service. <i>Irish Journal of Psychological Medicine</i> , 2021, , 1-14.	1.0	1
839	Social cognition and its relationship with sociodemographic, clinical, and psychosocial variables in first-episode psychosis. <i>Psychiatry Research</i> , 2021, 302, 114040.	3.3	3
840	Magnetic resonance imaging of brain anomalies in adult and pediatric schizophrenia patients: Experience of a Romanian tertiary hospital. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1098.	1.8	0
841	Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs. <i>Psychological Medicine</i> , 2023, 53, 1371-1378.	4.5	4
842	Sleep Disturbance in Individuals at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 111-121.	4.3	15
843	Validity and reliability of the Vigour Assessment Scale in avolitional schizophrenia outpatients. <i>Schizophrenia Research</i> , 2021, 235, 36-43.	2.0	5
844	How far to go in deconstructing negative symptoms? Behavioural and neural level evidence for the amotivation domain. <i>Schizophrenia Research</i> , 2021, 236, 41-47.	2.0	8
845	Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2021, 26, 100205.	1.3	2
846	Network analysis of cognitive deficit in patients with schizophrenia spectrum disorders. <i>Schizophrenia Research: Cognition</i> , 2021, 26, 100213.	1.3	10

#	ARTICLE	IF	CITATIONS
847	Intelligent Advanced User Interfaces for Monitoring Mental Health Wellbeing. Lecture Notes in Computer Science, 2021, , 83-95.	1.3	1
848	Asenapine: an atypical antipsychotic with atypical formulations. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110352.	2.7	11
849	Integrated Cognitive-Behavioral Social Skills Training and Compensatory Cognitive Training for Negative Symptoms of Psychosis: Effects in a Pilot Randomized Controlled Trial. Schizophrenia Bulletin, 2022, 48, 359-370.	4.3	6
850	Suicidal ideation in schizophrenia: A cross-sectional study in a tertiary mental hospital in North-East India. Indian Journal of Psychiatry, 2021, 63, 179.	0.7	3
851	Associations of Comorbid Obsessive-Compulsive Symptoms with Psychotic and Affective Symptoms and General Functioning. , 2015, , 77-88.		5
852	Sleep disturbance and quality of life in clinically stable inpatients with schizophrenia in rural China. Quality of Life Research, 2020, 29, 2759-2768.	3.1	8
853	Association Between Psychopathology and Suicidal Behavior In Schizophrenia. Crisis, 2013, 34, 374-381.	1.2	18
854	Biological motion sensitivity, but not interpersonal predictive coding is impaired in schizophrenia.. Journal of Abnormal Psychology, 2018, 127, 305-313.	1.9	18
855	Hope and its dimensions in relation to clinical recovery: A cross-sectional study among people with psychotic disorders.. Psychiatric Rehabilitation Journal, 2019, 42, 139-146.	1.1	7
856	The multidimensional construct of resilience across the psychosis spectrum: Evidence of alterations in people with early and prolonged psychosis.. Psychiatric Rehabilitation Journal, 2020, 43, 225-233.	1.1	5
857	Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study. Pharmacogenomics Journal, 2020, 20, 638-646.	2.0	4
858	Do Unremitted Psychotic Symptoms Have an Effect on the Brain? A 2-Year Follow-up Imaging Study in First-Episode Psychosis. Schizophrenia Bulletin Open, 2020, 1, sgaa039.	1.7	7
859	Psychometric Properties of the Japanese Version of the Calgary Depression Scale for Schizophrenics. Journal of Nervous and Mental Disease, 2000, 188, 237-239.	1.0	25
860	Best Clinical Practice with Ziprasidone: Update After One Year of Experience. Journal of Psychiatric Practice, 2002, 8, 81-97.	0.7	42
862	Cognitive functioning in young people with first episode psychosis: relationship to diagnosis and clinical characteristics. Australian and New Zealand Journal of Psychiatry, 2004, 38, 501-510.	2.3	13
863	Clinical profiles, scope and general findings of the Western Sydney First Episode Psychosis Project. Australian and New Zealand Journal of Psychiatry, 2005, 39, 36-43.	2.3	17
864	Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. BMJ Open, 2014, 4, e005708.	1.9	8
865	Depression in Schizophrenia: Methodological Artifact or Distinct Feature of the Illness?. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 431-440.	1.8	24

#	ARTICLE	IF	CITATIONS
866	Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. <i>Psychiatric Services</i> , 2006, 57, 1102-1109.	2.0	36
867	Which Is the Optimal Depression Rating Scale to Identify DSM-IV Depression in Schizophrenia ? A Diagnostic Validity Comparison of Five Mood Scales. <i>The Arab Journal of Psychiatry</i> , 2014, 25, 24-32.	0.1	3
868	Knowledge Gain by Psychoeducation for Patients with Schizophrenia: Associations with Sociodemographic Data, Psychopathology, Insight and Global Neurocognitive Performance. <i>International Journal of Clinical Psychiatry and Mental Health</i> , 2014, 2, 111-121.	0.3	3
869	The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms. <i>PLoS ONE</i> , 2013, 8, e68650.	2.5	27
870	Validation of the Arabic Version of Calgary Depression Scale for Schizophrenia. <i>PLoS ONE</i> , 2016, 11, e0162304.	2.5	15
871	Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 152-161.	2.4	64
872	Frontal fasciculi and psychotic symptoms in antipsychotic-naïve patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 133-141.	2.4	44
873	Cerebral blood flow in striatal regions is associated with apathy in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 102-110.	2.4	15
874	A depressÃ£o na esquizofrenia. <i>Revista Brasileira De Psiquiatria</i> , 2000, 22, 27-30.	1.7	7
875	DepressÃ£o em esquizofrenia. <i>Revista Brasileira De Psiquiatria</i> , 2002, 24, 86-93.	1.7	3
878	Development and Long-Term Acceptability of ExPRESS, a Mobile Phone App to Monitor Basic Symptoms and Early Signs of Psychosis Relapse. <i>JMIR MHealth and UHealth</i> , 2019, 7, e11568.	3.7	50
879	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , 2020, 9, e15058.	1.0	24
880	Mobile-Assisted Cognitive Behavioral Therapy for Negative Symptoms: Open Single-Arm Trial With Schizophrenia Patients. <i>JMIR Mental Health</i> , 2020, 7, e24406.	3.3	10
881	NEUROCOGNITIVE PROFILES OF PATIENTS WITH THE FIRST EPISODE OF PSYCHOSIS AND SCHIZOPHRENIA DO NOT DIFFER QUALITATIVELY: A NESTED CROSS-SECTIONAL STUDY. <i>Psychiatria Danubina</i> , 2019, 31, 43-53.	0.4	6
882	Burnout and Related Factors in Caregivers of outpatients with Schizophrenia. , 2017, 1, 001-011.		6
883	Prevalencia de la depresiÃ³n en EspaÃ±a: AnÃ¡lisis de los Ãºltimos 15 aÃ±os. <i>European Journal of Investigation in Health, Psychology and Education</i> , 2015, 5, 267.	1.9	12
884	Psychological approaches to understanding and promoting recovery in psychosis and bipolar disorder: a mixed-methods approach. <i>Programme Grants for Applied Research</i> , 2016, 4, 1-272.	1.0	12
885	A health promotion intervention to improve lifestyle choices and health outcomes in people with psychosis: a research programme including the IMPaCT RCT. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-124.	1.0	3

#	ARTICLE	IF	CITATIONS
886	Prevalence, Factorial Structure, and Clinical Correlates of First Rank Symptoms in Urban, African-American Patients with First-Episode Nonaffective Psychosis. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 2, 59-69.	1.4	2
887	Depressive Symptoms in Schizophrenia Outpatientsâ€”Prevalence and Clinical Correlates. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 2, 127-135.	1.4	9
888	Early Medication Adherence and Insight Change in First-Episode Psychosis. <i>Clinical Schizophrenia and Related Psychoses</i> , 2010, 3, 201-208.	1.4	5
889	â€œExtendedâ€•Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1042-1048.	2.2	58
890	Increased Systemic Cortisol Metabolism in Patients With Schizophrenia and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1515-1521.	2.2	44
891	Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 170-179.	2.2	56
892	Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study. <i>Industrial Psychiatry</i> , 2014, 23, 27.	0.8	10
893	A study of physical anhedonia as a trait marker in schizophrenia. <i>Industrial Psychiatry</i> , 2018, 27, 235.	0.8	2
894	Psychosocial Factors Contributing to Suicidal Ideation in Hospitalized Schizophrenia Patients in Korea. <i>Psychiatry Investigation</i> , 2010, 7, 79.	1.6	38
895	Prominent Clinical Dimension, Duration of Illness and Treatment Response in Schizophrenia: A Naturalistic Study. <i>Psychiatry Investigation</i> , 2012, 9, 354.	1.6	21
896	Factor Structure of the Clinician-Rated Dimensions of Psychosis Symptom Severity in Patients with Schizophrenia. <i>Psychiatry Investigation</i> , 2016, 13, 253.	1.6	13
897	Design and Methodology of the Korean Early Psychosis Cohort Study. <i>Psychiatry Investigation</i> , 2017, 14, 93.	1.6	19
898	Influence of different second generation antipsychotics on the QTc interval: A pragmatic study. <i>World Journal of Psychiatry</i> , 2016, 6, 442.	2.7	11
899	Dehydroepiandrosterone sulfate and testosterone levels correlate with negative symptoms in male patients with schizophrenia. <i>The Egyptian Journal of Psychiatry: Official Journal of the Egyptian Psychiatric Association</i> , 2012, 33, 181.	0.1	4
900	Social capital, pathway to care and duration of untreated psychosis: Findings from a low- and middle-income country context. <i>South African Journal of Psychiatry</i> , 2012, 18, .	0.4	2
901	Psychometric Properties of the Korean Version of the Clinical Language Disorder Rating Scale (CLANG). <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 49-56.	2.0	5
902	Gender-specific Associations of the Brain-derived Neurotrophic Factor<i>Val66Met</i>Polymorphism with Neurocognitive and Clinical Features in Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 270-278.	2.0	15
903	One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 434-444.	2.0	4

#	ARTICLE	IF	CITATIONS
904	Estimating the minimum important difference for the questionnaire about the Process of Recovery (QPR): an anchor-based approach. Psychosis, 2021, 13, 220-230.	0.8	3
905	Recent Stressful Life Events and Suicidal Ideation in Schizophrenia. Journal of Nervous and Mental Disease, 2021, Publish Ahead of Print, .	1.0	1
907	The Relationship between the Therapeutic Alliance and Suicidal Experiences in People with Psychosis Receiving Therapy. International Journal of Environmental Research and Public Health, 2021, 18, 10706.	2.6	2
908	Validity and reliability of a Persian version of the self- evaluation of negative symptoms (SNS). BMC Psychiatry, 2021, 21, 516.	2.6	1
909	Intermittent theta burst stimulation of cerebellar vermis enhances fronto-cerebellar resting state functional connectivity in schizophrenia with predominant negative symptoms: A randomized controlled trial. Schizophrenia Research, 2021, 238, 108-120.	2.0	27
910	Risperidona en la esquizofrenia cr�nica: un estudio de cambio al descubierto con verificaci�n detallada y seguimiento de dos a�os de pacientes en medicaci�n depot. European Psychiatry (Ed Tj ETQq1 1 0.784314 rgBT /Overl	0.0	0
911	Uso auxiliar de la reboxetina en la esquizofrenia. European Psychiatry (Ed Espa�ola), 2005, 12, 107-110.	0.0	0
912	DEPRESSION AND FUNCTIONAL LEVEL IN SCHIZOPHRENIA: A COMPARISON BETWEEN CHRONIC HOSPITALISED IN-PATIENTS AND COMMUNITY CARE PATIENTS. Journal of the University of Malaya Medical Centre, 2007, 10, 31-36.	0.0	0
913	Evaluation of symptomatology on schizophrenia. Medical Psychiatry, 2009, , 32-38.	0.2	0
915	Depression and Suicidality. , 2012, , 9-14.		0
917	TERAPIA DE ACTIVACI�N CONDUCTUAL PARA LA DEPRESI�N: APLICACI�N A UN PACIENTE CON ESQUIZOFRENIA PARANOIDE. An�lisis Y Modificaci�n De Conducta, 2012, 1, .	0.1	1
918	Hedonic Capacity and Related Factors in Schizophrenia and Schizoaffective Disorder. , 2014, , 55-103.		0
920	Depresi�n en pacientes con esquizofrenia ingresados en servicios de agudos del Hospital Psiqui�trico de La Habana. Revista De Psicolog�a (Peru), 2015, 33, 131-151.	0.2	0
921	Rate of depression among patients with schizophrenia. Zanco Journal of Medical Sciences, 2016, 20, 1180-1185.	0.1	1
922	STUDY OF SUICIDE ATTEMPTS IN SCHIZOPHRENIA. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 3295-3302.	0.0	0
923	STUDY OF FACTORS AFFECTING SUICIDE ATTEMPTS IN PERSONS WITH SCHIZOPHRENIA. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 4219-4225.	0.0	0
925	Identifying the ‘‘Therapy Targets’’ for Treating the Negative Symptoms of Psychosis Using Cognitive Behavioral Therapy. Journal of Cognitive Psychotherapy, 2018, 32, 203-220.	0.4	1
926	Comparison of clinical characteristics between patients on clozapine treatment with those taking combined antipsychotics in schizophrenia considering the impact of OCD comorbidity. Noropsikiyatri Arsivi, 2019, 56, 219-223.	0.3	3

#	ARTICLE	IF	CITATIONS
928	BAKIM VERÄ°CÄ°NÄ°N DUYGU Ä°FADESÄ°NÄ°N VE BAÄžLANMA STÄ°LÄ°NÄ°N ÄžÄ°ZOFRENÄ° HASTALARININ OKSÄ°DATÄ°F STRES DÄ°ETKÄ°SÄ°. Kocatepe TÄ±p Dergisi, 2019, 20, 121-130.	0.1	0
930	Äžizofreni hastalarÄ±nÄ±n bakÄ±m verenlerinde duygu dÄ±Äžva vurum ve mizaÄš Ä¶zellikleri iliÄžkisi. Celal Bayar Äœniversitesi SaÄžlÄ±k Bilimleri EnstitÄ±sÄ± Dergisi, 0, , .	0.3	0
931	Factor structure of the Albanian version of the Clinical Assessment Interview for Negative Symptoms (CAINS): Associations with the Brief Symptoms Inventory (BSI). Global Psychiatry, 2020, .	2.0	0
932	Assessing The Relationship Between Clinical Characteristics and Obsessive-Compulsive Disorder Comorbidity and Obsessive-Compulsive Symptoms in Patients With Schizophrenia. Anadolu KliniÄži TÄ±p Bilimleri Dergisi, 0, , .	0.4	0
933	CogniciÄ±n social en pacientes con un primer episodio psicÄ±tico. Revista De PsiquiatrÄ±a Y Salud Mental, 2020, , .	1.8	0
935	Clinical Correlates of Treatment Adherence and Insight in Patients with Schizophrenia. Archives of Clinical and Experimental Medicine, 2020, 5, 95-99.	0.0	3
936	Trends in (not) using scales in major depression: A categorization and clinical orientation. European Psychiatry, 2020, 63, e91.	0.2	8
938	Clinical correlates of obsessive-compulsive disorder comorbidity in patients with schizophrenia. Indian Journal of Psychiatry, 2020, 62, 51.	0.7	6
939	Outcome Measurement in Schizophrenia: Challenges and Barriers. , 2020, , 91-124.		1
940	Course of insight, depression and suicidality in inpatients with firstÄ±episode schizophrenia who received group psychoeducation. Microbial Biotechnology, 2021, , .	1.7	0
941	Structure and stability of symptoms in first episode psychosis: a longitudinal network approach. Translational Psychiatry, 2021, 11, 567.	4.8	14
942	The Most Commonly Used Instruments in Research on Functioning in Schizophrenia. European Psychologist, 2020, 25, 283-292.	3.1	6
943	Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 1Q Tf 50 262	0.8	9
945	Age at Onset and Social Cognitive Impairment in Clinically Stabilized Patients with Schizophrenia: An Ecological Cross-Sectional Study. Iranian Journal of Psychiatry, 2018, 13, 84-93.	0.7	3
946	Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. Psychopharmacology Bulletin, 2018, 48, 25-61.	0.0	9
947	Early Psychosis Intervention-Spreading Evidence-based Treatment (EPI-SET): protocol for an effectiveness-implementation study of a structured model of care for psychosis in youth and emerging adults. BMJ Open, 2020, 10, e034280.	1.9	3
948	Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study. BMJ Open, 2021, 11, e046552.	1.9	5
949	<i>Ä±Ä±Care co-ordinator in my pocketÄ±™: a feasibility study of mobile assessment and therapy for psychosis (TechCare). BMJ Open, 2021, 11, e046755.	1.9	8

#	ARTICLE	IF	CITATIONS
950	Metacognitive training modified for negative symptoms: A feasibility study. <i>Clinical Psychology and Psychotherapy</i> , 2022, 29, 1068-1079.	2.7	2
951	Eye Movements and Cognitive Functioning in Patients With Schizophrenia Spectrum Disorders: Network Analysis. <i>Frontiers in Psychiatry</i> , 2021, 12, 736228.	2.6	2
952	Manualized group cognitive behavioral therapy for social anxiety in first-episode psychosis: a randomized controlled trial. <i>Psychological Medicine</i> , 2023, 53, 3335-3344.	4.5	2
953	Reliability of the Calgary depression scale for schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2022, 240, 32-45.	2.0	5
954	Clinical insight and cognitive functioning as mediators in the relationships between symptoms of psychosis, depression, and suicide ideation in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2022, 147, 85-93.	3.1	4
955	Multidimensional predictors of negative symptoms in antipsychotic-naïve first-episode psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E21-E31.	2.4	5
956	Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study). <i>Frontiers in Psychiatry</i> , 2021, 12, 770592.	2.6	4
957	Suicidal behaviour in first-episode psychosis: The relevance of age, perceived stress and depressive symptoms. <i>Clinical Psychology and Psychotherapy</i> , 2022, 29, 1364-1373.	2.7	4
958	Primary and Secondary Negative Symptoms in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 766692.	2.6	31
960	Comparison of clinical features and 1-year outcomes between patients with psychotic disorder not otherwise specified and those with schizophrenia. <i>Microbial Biotechnology</i> , 2022, 16, 1309-1318.	1.7	5
961	Association between C-reactive protein levels and antipsychotic treatment during 12-months follow-up period after acute psychosis. <i>Schizophrenia Research</i> , 2022, 241, 174-183.	2.0	3
962	Psychometric instruments for the assessment of depressive symptoms in patients with delusional disorder: A systematic review. <i>Psychiatry Research</i> , 2022, 310, 114435.	3.3	0
963	Early Psychosis Intervention-Spreading Evidence-based Treatment (EPI-SET): protocol for an effectiveness-implementation study of a structured model of care for psychosis in youth and emerging adults. <i>BMJ Open</i> , 2020, 10, e034280.	1.9	8
964	Post-Psychotic Depression: An Updated Review of the Term and Clinical Implications. <i>Psychopathology</i> , 2022, 55, 82-92.	1.5	9
965	The Time is Ripe for a Consensus Definition of Clinical Recovery in First-episode Psychosis: Suggestions Based on a 10-Year Follow-up Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 839-849.	4.3	9
966	COVID-19 and psychosis, depression, obsession and quality of life in Lebanese patients with schizophrenia: Any changes after 5-months of quarantine?. <i>BMC Psychology</i> , 2022, 10, 32.	2.1	11
967	Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers. <i>Psychological Medicine</i> , 2022, , 1-10.	4.5	3
968	Psychosocial Therapy in Schizophrenic Patients with Depression. <i>The Bangkok Medical Journal</i> , 2022, 18, 61-64.	0.0	0

#	ARTICLE	IF	CITATIONS
969	Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. <i>Acta Neuropsychiatrica</i> , 2022, 34, 282-288.	2.1	2
970	Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. <i>NPJ Schizophrenia</i> , 2022, 8, 29.	3.6	5
971	The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 18.	3.6	0
972	Interleukin-18 signaling system links to agitation in severe mental disorders. <i>Psychoneuroendocrinology</i> , 2022, 140, 105721.	2.7	6
973	Ranking Tailoring Variables for Constructing Individualized Treatment Rules: An Application to Schizophrenia. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2022, 71, 309-330.	1.0	1
974	Tracing Links Between Early Auditory Information Processing and Negative Symptoms in Schizophrenia: An ERP Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 790745.	2.6	9
975	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. <i>Brain Sciences</i> , 2021, 11, 1632.	2.3	12
976	Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis. <i>JAMA Network Open</i> , 2021, 4, e2140858.	5.9	14
977	Effect of Probiotics on the Traumatic Brain Injury. <i>Forbes Tıp Dergisi</i> , 2022, 3, 59-67.	0.1	0
982	Sex differences in antipsychotic-related triglyceride levels are associated with metabolic hormone differences in patients with severe mental disorders. <i>Schizophrenia Research</i> , 2022, 243, 55-63.	2.0	2
983	Use of olanzapine for elderly patients with psychotic disorders: a review. <i>Annals of Clinical Psychiatry</i> , 2001, 13, 201-213.	0.6	8
985	Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, 795866.	2.6	8
986	Sex-specific associations in verbal memory brain circuitry in early psychosis. <i>Journal of Psychiatric Research</i> , 2022, 151, 411-418.	3.1	2
987	Influence of positive and negative symptoms on hedonic and eudaemonic well-being in people with schizophrenia: A longitudinal analysis from the EuroSc study. <i>Schizophrenia Research</i> , 2022, 244, 21-28.	2.0	2
988	Modifiable predictors of self-reported and performance-based functioning in individuals with schizophrenia-spectrum disorders and high levels of negative symptoms. <i>Journal of Psychiatric Research</i> , 2022, 151, 347-353.	3.1	4
989	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-174.	2.8	16
990	Validation of the Brazilian version of the Hinting Task and Facial Emotion Recognition Test (FERT-100) in patients with schizophrenia. <i>Dementia E Neuropsychologia</i> , 0, , .	0.8	0
991	Enhancing future-directed thinking in people with first-episode psychosis using a guided imagery intervention. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2022, 76, 101738.	1.2	2

#	ARTICLE	IF	CITATIONS
992	Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMiSE trial. <i>European Psychiatry</i> , 2022, 65, .	0.2	4
993	Serum Levels and in vitro CX3CL1 (Fractalkine), CXCL8, and IL-10 Synthesis in Phytohemagglutinin-Stimulated and Non-stimulated Peripheral Blood Mononuclear Cells in Subjects With Schizophrenia. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	1
994	Decision Value Signals in the Ventromedial Prefrontal Cortex and Motivational and Hedonic Symptoms Across Mood and Psychotic Disorders. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
995	Association between Peripheral Inflammatory Cytokines and Cognitive Function in Patients with First-Episode Schizophrenia. <i>Journal of Personalized Medicine</i> , 2022, 12, 1137.	2.5	10
996	Emotional abuse and perceived stress: The most relevant factors in suicide behavior in first-episode psychosis patients. <i>Psychiatry Research</i> , 2022, 315, 114699.	3.3	7
997	Tetrahydrobiopterin deficiency in schizophrenia: Biochemical and clinical aspects. <i>Journal of Psychiatric Research</i> , 2022, 153, 141-148.	3.1	2
998	A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	3
999	The impact of mental illness on self-concept: relationship between engulfment, cognitive insight, and depression in schizophrenia. <i>Psychosis</i> , 2023, 15, 394-405.	0.8	0
1000	DNA Methylation Profiles of the DRD2 and NR3C1 Genes in Patients with Recent-Onset Psychosis. <i>Disease Markers</i> , 2022, 2022, 1-13.	1.3	3
1001	Differences of affective and non-affective psychoses in early intervention services from Latin America. <i>Journal of Affective Disorders</i> , 2022, 316, 83-90.	4.1	4
1002	Sex-specific associations between metabolic hormones, severe mental disorders and antipsychotic treatment. <i>Psychoneuroendocrinology</i> , 2022, 146, 105927.	2.7	0
1003	Comparing adaptive coding of reward in bipolar I disorder and schizophrenia. <i>Human Brain Mapping</i> , 2023, 44, 523-534.	3.6	2
1004	Anxious-depressive symptoms after a first episode of schizophrenia: Response to treatment and psychopathological considerations from the 2-year "Parma Early Psychosis" program. <i>Psychiatry Research</i> , 2022, 317, 114887.	3.3	4
1005	Decision value signals in the ventromedial prefrontal cortex and motivational and hedonic symptoms across mood and psychotic disorders. <i>NeuroImage: Clinical</i> , 2022, 36, 103227.	2.7	2
1006	Depression Mediates the Relationships between Hallucinations, Delusions, and Social Isolation in First-Episode Psychosis. <i>Social Work Research</i> , 2022, 46, 332-341.	0.6	1
1007	Behavioural phenotypes of intrinsic motivation in schizophrenia determined by cluster analysis of objectively quantified real-world performance. , 2022, 8, .		0
1008	Three-year outcomes and predictors for full recovery in patients with early-stage psychosis. , 2022, 8, .		6
1009	Psychopathology: Rating Scales for the Assessment of Mental Status. , 2022, , 245-267.		0

#	ARTICLE	IF	CITATIONS
1010	The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia. <i>Biomedicines</i> , 2022, 10, 2939.	3.2	3
1011	Negative symptoms in alcohol use disorder: A pilot study applying the two-factor model of negative symptoms to patients with alcohol use disorder. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	0
1012	Cerebellar stimulation in schizophrenia: A systematic review of the evidence and an overview of the methods. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	3
1013	Prevalence of loneliness and its correlates among patients with schizophrenia. <i>International Journal of Social Psychiatry</i> , 2023, 69, 906-915.	3.1	4
1014	Incidence rate and distinctive characteristics of first episode psychosis during the COVID-19 pandemic: a multicenter observational study. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
1016	The Association of the Oral Microbiota with the Effects of Acid Stress Induced by an Increase of Brain Lactate in Schizophrenia Patients. <i>Biomedicines</i> , 2023, 11, 240.	3.2	5
1017	Third-generation genome sequencing implicates medium-sized structural variants in chronic schizophrenia. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	0
1018	Retrospectively assessed childhood trauma experiences are associated with illness severity in mental disorders adjusted for symptom state. <i>Psychiatry Research</i> , 2023, 320, 115045.	3.3	6
1019	Predictors of full recovery in patients with early stage schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2023, 320, 115035.	3.3	0
1020	Mediating effect of genome-wide DNA methylation on suicidal ideation induced by stressful events. <i>Psychiatric Genetics</i> , 2023, 33, 26-33.	1.1	0
1021	Predictors of treatment attrition of cognitive health interventions in first episode psychosis. <i>Microbial Biotechnology</i> , 0, , .	1.7	0
1022	Risk factors, clinical correlates, and social functions of Chinese schizophrenia patients with drug-induced parkinsonism: A cross-sectional analysis of a multicenter, observational, real-world, prospective cohort study. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
1023	Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2024, 274, 181-193.	3.2	1
1024	Victimization in schizophrenia and its relation to violence. <i>Schizophrenia Research</i> , 2023, 255, 52-58.	2.0	0
1025	Effects of COVID-19 pandemic on depression in patients with schizophrenia: A mini-review of the current evidence. <i>Journal of Affective Disorders</i> , 2023, 332, 143-149.	4.1	2
1026	Higher lymphocyte count associated with larger hippocampal volume and fewer depressive symptoms in drug-naïve first-episode psychosis. <i>European Neuropsychopharmacology</i> , 2023, 69, 47-55.	0.7	1
1027	Depressive symptoms are specifically related to speech pauses in schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2023, 321, 115079.	3.3	1
1028	Five-year illness trajectories across racial groups in the UK following a first episode psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 0, , .	3.1	4

#	ARTICLE	IF	CITATIONS
1029	Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	1
1030	The relevance of processing speed in the functioning of people with first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2023, 160, 171-176.	3.1	1
1031	Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report. <i>International Clinical Psychopharmacology</i> , 2023, 38, 275-280.	1.7	2
1032	Exploring engagement with the CBT-informed Actissist smartphone application for early psychosis. <i>Journal of Mental Health</i> , 2023, 32, 643-654.	1.9	4
1033	A cognitive-behavioral suicide prevention treatment for adults with schizophrenia spectrum disorders in community mental health: preliminary findings of an open pilot study. <i>Social Work in Mental Health</i> , 2023, 21, 538-560.	1.0	1
1034	Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. <i>Schizophrenia Research</i> , 2023, 254, 178-189.	2.0	3
1035	Social Stigma Towards Mental Health Problems in Spain: A Systematic Review. <i>Clinica Y Salud</i> , 2023, 34, 23-34.	0.8	3
1036	Oxidative Stress Biomarkers among Schizophrenia Inpatients. <i>Brain Sciences</i> , 2023, 13, 490.	2.3	5
1037	Immunological routine laboratory parameters at admission influence the improvement of positive symptoms in schizophrenia patients after pharmacological treatment. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	4
1038	Psychotic Relapse Prediction in Schizophrenia Patients Using A Personalized Mobile Sensing-Based Supervised Deep Learning Model. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2023, 27, 3246-3257.	6.3	4
1039	Influences of race and clinical variables on psychiatric genetic research participation: Results from a schizophrenia sample. <i>PLoS ONE</i> , 2023, 18, e0284356.	2.5	2
1040	Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2023, 43, 246-258.	1.4	2
1043	Psychological/Personal recovery and its correlates in patients with first episode psychosis. <i>International Journal of Social Psychiatry</i> , 0, , 002076402311645.	3.1	0
1044	Six-year trajectories and associated factors of positive and negative symptoms in schizophrenia patients, siblings, and controls: Genetic Risk and Outcome of Psychosis (GROUP) study. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
1045	Factors associated with suicide attempts in first-episode psychosis during the first two years after onset. <i>Psychiatry Research</i> , 2023, 325, 115232.	3.3	2
1046	A Systematic Review and Meta-Analysis of the Association Between Psychopathology and Social Functioning in Schizophrenia. <i>Schizophrenia Bulletin</i> , 0, , .	4.3	4
1047	Pterin metabolism, inflammation and oxidative stress biochemical markers in schizophrenia: Factor analysis and assessment of clinical symptoms associations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2023, 127, 110823.	4.8	1
1048	Reward processing in schizophrenia and its relation to Mu opioid receptor availability and negative symptoms: A [11C]-carfentanil PET and fMRI study. <i>NeuroImage: Clinical</i> , 2023, 39, 103481.	2.7	0

#	ARTICLE	IF	CITATIONS
1049	A Digital System (YouXin) to Facilitate Self-Management by People With Psychosis in China: Protocol for a Nonrandomized Validity and Feasibility Study With a Mixed Methods Design. JMIR Research Protocols, 0, 12, e45170.	1.0	1
1050	Sociodemographic and clinical risk factors associated with suicidal ideation and attempt during a 2-year early intervention program for first-episode psychosis. Schizophrenia Research, 2023, 258, 61-68.	2.0	1
1051	Cognitive subgroups and the relationships with symptoms, psychosocial functioning and quality of life in first-episode non-affective psychosis: a cluster-analysis approach. Frontiers in Psychiatry, 0, 14, .	2.6	0
1052	Moment-to-moment affective dynamics in schizophrenia and bipolar disorder. European Psychiatry, 0, , 1-38.	0.2	1
1053	Expression of ANK3 moderates the association between childhood trauma and affective traits in severe mental disorders. Scientific Reports, 2023, 13, .	3.3	0
1054	The effect of vortioxetine on anhedonia in patients with schizophrenia. International Journal of Psychiatry in Medicine, 0, , .	1.8	0
1055	The relationship between purpose in life and depression and anxiety: A meta-analysis. Journal of Clinical Psychology, 2023, 79, 2736-2767.	1.9	6
1056	Network analysis of inflammation and symptoms in recent onset schizophrenia and the influence of minocycline during a clinical trial. Translational Psychiatry, 2023, 13, .	4.8	0
1057	Inflammatory markers of symptomatic remission at 6 months in patients with first-episode schizophrenia. , 2023, 9, .		1
1058	Effects of group music therapy on symptoms and functional recovery in outpatients with chronic psychoses: A randomized controlled trial. Nordic Journal of Music Therapy, 2024, 33, 122-141.	1.1	0
1059	Rates and correlates of medication non-adherence behaviors and attitudes in adult patients with early psychosis. Social Psychiatry and Psychiatric Epidemiology, 0, , .	3.1	0
1060	Impulsivity across severe mental disorders: a cross-sectional study of immune markers and psychopharmacotherapy. BMC Psychiatry, 2023, 23, .	2.6	0
1061	Impact of negative symptoms on health-related quality of life in schizophrenia. Frontiers in Psychiatry, 0, 14, .	2.6	1
1062	Functional and clinical outcomes of delusional disorder and schizophrenia patients after first episode psychosis: a 4-year follow-up study. BMC Psychiatry, 2023, 23, .	2.6	0
1063	Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey. Schizophrenia Research, 2023, , .	2.0	1
1064	Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial. Trials, 2023, 24, .	1.6	0
1065	User engagement in a randomised controlled trial for a digital health intervention for early psychosis (Actissist 2.0 trial). Psychiatry Research, 2023, 329, 115536.	3.3	1
1066	The impact of Pilates exercise for depression symptoms in female patients: A systematic review and meta-analysis. Medicine (United States), 2023, 102, e35419.	1.0	1

#	ARTICLE	IF	CITATIONS
1067	Psychometric properties of the Clinical Assessment Interview for Negative Symptoms (CAINS) in patients with depression and its relationship to affective symptoms. <i>Annals of General Psychiatry</i> , 2023, 22, .	2.7	0
1068	Association between suicidal ideation and cognitive function in young patients with schizophrenia spectrum disorder. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	1
1069	Cross-modal associative memory impairment in schizophrenia. <i>Neuropsychologia</i> , 2023, 191, 108721.	1.6	0
1070	Patient-reported outcome measures in early psychosis: Evaluating the psychometric properties of the single-item self-reported health and self-reported mental health measures in Chennai, India and Montreal, Canada. <i>Microbial Biotechnology</i> , 0, , .	1.7	1
1071	High-definition transcranial direct current stimulation for treating cognitive and negative symptoms in chronic schizophrenia – A sham-controlled proof of concept study. , 0, 1, 46-53.		0
1072	Mindfulness, psychological flexibility and their relationship with psychopathology in persons with schizophrenia-spectrum-disorders and healthy controls – A multicenter cross-sectional study. <i>Psychiatry Research</i> , 2023, 330, 115591.	3.3	0
1073	Relationship between thyroid-stimulating hormone, BDNF levels, and hippocampal volume in antipsychotic-naïve first-episode psychosis patients. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	1
1074	Late onset psychosis treatment with adjunctive medicines. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	0
1075	Improving depressive symptoms in patients with schizophrenia using bilateral bipolar-nonbalanced prefrontal tDCS: Results from a double-blind sham-controlled trial. <i>Journal of Affective Disorders</i> , 2024, 349, 165-175.	4.1	0
1076	Effects of right prefrontal theta-burst transcranial magnetic stimulation or transcranial direct current stimulation on apathy in patients with schizophrenia: A multicenter RCT. <i>Psychiatry Research</i> , 2024, 333, 115743.	3.3	0
1078	Sex differences in autonomic adverse effects related to antipsychotic treatment and associated hormone profiles. , 2024, 10, .		0
1079	The Relationship Between Depressive Symptoms and Psychological Variables in Patients With Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2024, 30, 13-22.	0.7	0
1080	Differences in metabolic biomarkers in people with schizophrenia who are of Mexican descent compared to non-Hispanic whites. <i>Psychiatry Research</i> , 2024, 334, 115788.	3.3	0
1081	The Nature of Mental Imagery and its Relationship with Amotivational Psychopathology in People with Schizophrenia Spectrum Disorders. <i>Behavior Therapy</i> , 2024, , .	2.4	0
1082	Correlation of allostatic load and perceived stress with clinical features in first-episode schizophrenia. <i>Journal of Psychiatric Research</i> , 2024, 172, 156-163.	3.1	0
1083	Association of Blood Metabolomics Biomarkers with Brain Metabolites and Patient-Reported Outcomes as a New Approach in Individualized Diagnosis of Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2294.	4.1	0
1084	A good life with psychosis: rate of positive outcomes in first-episode psychosis at 10-year follow-up. <i>Psychological Medicine</i> , 0, , 1-10.	4.5	0
1085	Investigation of the effect of goal-oriented dance movement therapy on depressive symptoms in people with schizophrenia: a rater-blinded randomised controlled study. <i>International Journal of Therapy and Rehabilitation</i> , 2024, 31, 1-10.	0.3	0

#	ARTICLE	IF	CITATIONS
1086	Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2024, 50, 496-512.	4.3	0
1087	Mindfulness-Based Interventions for People Experiencing Psychosis: A Randomized Feasibility Study. Mindfulness, 2024, 15, 804-818.	2.8	0
1088	Exploring parenthood in first episode of psychosis: the potential role of the offspring in the outcome of women. Archives of Women's Mental Health, 0, , .	2.6	0
1089	Effectiveness of family metacognitive training in mothers with psychosis and their adolescent children: a multicenter study protocol. Frontiers in Psychology, 0, 15, .	2.1	0
1090	Co-design and evaluation of a youth-informed organisational tool to enhance trauma-informed practices in the UK public sector: a study protocol. BMJ Open, 2024, 14, e078545.	1.9	0